



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2400642 A1 2001/08/30

(21) **2 400 642**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2001/02/13

(87) Date publication PCT/PCT Publication Date: 2001/08/30

(85) Entrée phase nationale/National Entry: 2002/08/19

(86) N° demande PCT/PCT Application No.: US 2001/004625

(87) N° publication PCT/PCT Publication No.: 2001/062919

(30) Priorité/Priority: 2000/02/23 (60/184,732) US

(51) Cl.Int.⁷/Int.Cl.⁷ C12N 15/12, A61K 31/00, A61K 33/00,
C07K 14/435, C12N 15/62, G01N 33/52

(71) Demandeur/Applicant:
VERTEX PHARMACEUTICALS (SAN DIEGO) LLC, US

(72) Inventeurs/Inventors:
NELSON, DAVID, US;
ZAMAIRA, ELIZE, US;
TSIEN, ROGER, US


(74) Agent: MBM & CO.

(54) Titre : PROTEINES FLUORESCENTES MODIFIEES

(54) Title: MODIFIED FLUORESCENT PROTEINS

(57) Abrégé/Abstract:

Functional red fluorescent proteins, nucleic acids encoding them, and methods for their use.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT
(10) International Publication Number
WO 01/62919 A1

- (51) International Patent Classification⁷: C12N 15/12, C07K 14/435, C12N 15/62, G01N 33/52, A61K 31/00, 33/00

(21) International Application Number: PCT/US01/04625

(22) International Filing Date: 13 February 2001 (13.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/184,732 23 February 2000 (23.02.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/184,732 (CON)
Filed on 23 February 2000 (23.02.2000)

(71) Applicant (for all designated States except US): AURORA BIOSCIENCES CORPORATION [US/US]; 11010 Torreyana Road, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NELSON, David [US/US]; 6540 Windward Ridge Way, San Diego, CA 92121 (US). ZAMAIRA, Elize [US/US]; 11890 Arborlake Way, San Diego, CA 92131 (US). TSIEN, Roger
- [US/US]; 8535 Nottingham Place, La Jolla, CA 92037 (US).

(74) Agent: HAILE, Lisa, A.; Gray Cary Ware & Freidenrich, Suite 1600, 4365 Executive Drive, San Diego, CA 92121-2189 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MODIFIED FLUORESCENT PROTEINS

(57) Abstract: Functional red fluorescent proteins, nucleic acids encoding them, and methods for their use.



WO 01/62919 A1

MODIFIED FLUORESCENT PROTEINS

FIELD OF THE INVENTION

The present invention relates generally to functional mutants of red fluorescent proteins, and methods for their use.

5

BACKGROUND OF THE INVENTION

Naturally fluorescent proteins are attractive as reporter molecules for cell based assays because of their bright visible fluorescence and ability to be expressed within living cells without the need to add exogenous co-factors or reagents.

10 Fluorescent proteins have been successfully exploited as markers of gene expression, tracers of cell lineage, fusion tags to monitor protein localization within living cells, and as fluorescent donors or acceptors for assays based on the use of fluorescent resonance energy transfer (FRET). Naturally fluorescent proteins have been characterized from a large number of species, however the green fluorescent
15 protein from *Aequorea victoria* is probably the most extensively studied example.

Aequorea green fluorescent protein (GFP) is a stable, proteolysis-resistant single polypeptide chain of 238 residues, and has two absorption maxima at around 395 and 475 nm (Tsien (1998) Annu. Rev. Biochem. 67 509-544). The relative amplitudes of these two peaks are sensitive to environmental factors (Ward &
20 Bokman (1982) Biochemistry 21:4535-4540, Ward et al. (1982) Photochem. Photobiol. 35 803-808) and illumination history (A. B. Cubitt et al. (1995) Trends Biochem. Sci. 20 448-455). Excitation at the primary absorption peak of 395 nm yields an emission maximum at 508 nm with a quantum yield of 0.72-0.85 (Shimomura and Johnson (1962) J. Cell. Comp. Physiol. 59 223).

25 The fluorophore results from the autocatalytic cyclization of the polypeptide backbone between residues Ser⁶⁵ and Gly⁶⁷ and oxidation of the α - β bond of Tyr⁶⁶ (Cody et al., (1993) Biochemistry 32 1212-1218, Heim et al., (1994) Proc. Natl. Acad. Sci. USA 91 12501-12504). Mutation of Ser⁶⁵ to Thr (S65T) simplifies the excitation spectrum to a single peak at 488 nm of enhanced amplitude (Heim et al.,

(1995) Nature 373 664-665), which no longer gives signs of conformational isomers. The cDNA for the protein was cloned in 1992 and the protein has been extensively mutated (D.C. Prasher et al., (1992) Gene 111 229-33). Mutagenesis of GFP has resulted in the creation of a variety of mutants that have distinct spectral properties, improved brightness and enhanced expression and folding in mammalian cells compared to the native GFP, (SEQ. ID. NO.: 10), **Table 1.** (*Green Fluorescent Proteins*, Chapter 2, pages 19 to 47, edited Sullivan and Kay, Academic Press, U.S. Patent Nos: 5,625,048 to Tsien *et al.*, issued April 29, 1997; 5,777,079 to Tsien *et al.*, issued July 7, 1998; and U.S. Patent No. 5,804,387 to Cormack *et al.*, issued September 8, 1998). In many cases, these functional engineered fluorescent proteins have superior spectral properties to wild-type *Aequorea* GFP, and are preferred for use herein.

TABLE 1					
Mutants of Aequorea Green Fluorescent Proteins					
Mutations	Common Name	Quantum Yield (Φ) & Molar Extinction (ϵ)	Excitation & Emission Max	Relative Fluorescence At 37 °C	Sensitivity To Low pH % max F at pH 6
S65T type					
S65T, S72A, N149K, M153T, I167T	Emerald (SEQ. ID. NO.: 28)	$\Phi = 0.68$ $\epsilon = 57,500$	487 509	100	91
F64L, S65T, V163A		$\Phi = 0.58$ $\epsilon = 42,000$	488 511	54	43
F64L,S65T	EGFP	$\Phi = 0.60$ $\epsilon = 55,900$	488 507	20	57
S65T		$\Phi = 0.64$ $\epsilon = 52,000$	489 511	12	56
Y66H type					
F64L, Y66H, Y145F, V163A	P4-3E	$\Phi = 0.27$ $\epsilon = 22,000$	384 448	100	N.D.
F64L, Y66H, Y145F		$\Phi = 0.26$ $\epsilon = 26,300$	383 447	82	57
Y66H, Y145F	P4-3	$\Phi = 0.3$ $\epsilon = 22,300$	382 446	51	64
Y66H	BFP	$\Phi = 0.24$ $\epsilon = 21,000$	384 448	15	59
Y66W type					
S65A, Y66W, S72A, N146I, M153T, V163A	W1C	$\Phi = 0.39$ $\epsilon = 21,200$	435 495	100	82

F64L,S65T, Y66W, N146I, M153T, V163A	W1B	$\Phi = 0.4$ $\epsilon = 32,500$	434 452 476 (505)	80	71
Y66W, N146I, M153T, V163A	hW7	$\Phi = 0.42$ $\epsilon = 23,900$	434 452 476 (505)	61	88
Y66W			436 485	N.D.	N.D.
T203Y type					
S65G, S72A, K79R, T203Y	Topaz	$\Phi = 0.60$ $\epsilon = 94,500$	514 527	100	14
S65G, V68L, S72A, T203Y	10C	$\Phi = 0.61$ $\epsilon = 83,400$	514 527	58	21
S65G,V68L, Q69K, S72A, T203Y	h10C+	$\Phi = 0.71$ $\epsilon = 62,000$	516 529	50	54
S65G, S72A, T203H		$\Phi = 0.78$ $\epsilon = 48,500$	508 518	12	30
S65G, S72A T203F		$\Phi = 0.70$ $\epsilon = 65,500$	512 522	6	28
T203I type					
T203I, S72A, Y145F	Sapphire	$\Phi = 0.64$ $\epsilon = 29,000$	395 511	100	90
T203I T202F	H9	$\Phi = 0.6$ $\epsilon = 20,000$	395 511	13	80

X-ray crystallographic studies have clarified the protein structure and helped to elucidate the effect of mutations, environmental effects, and photochemical events that occur in wild-type and mutant forms of *Aequorea* GFP (Ormo et al., (1996) Science 273 1392-1395, Yang et al., (1996) Nat. Biotechnol. 14 1246-1251, Brejc et al., (1997) Proc. Natl. Acad. Sci. USA 94 2306-2311, Scharnagl et al., (1999) Biophys J. 77 1839-1857, Elsliger et al. (1999) Biochem. 38 5296-5301). These studies have provided a detailed molecular picture of the chromophore structure in *Aequorea* GFP and have enabled a precise understanding of how changes in the electronic environment around the chromophore lead to altered fluorescent properties.

Despite this unique understanding, current efforts to date have failed to create stable, well-defined, red fluorescent mutants of *Aequorea* GFP. Red fluorescent proteins (RFPs) are particularly attractive as fluorescent markers because red light is less phototoxic, is transmitted through tissues more efficiently, and is less scattered than blue or UV light sources. Additionally cells typically exhibit less autofluorescence when illuminated with red light compared to UV light.

The present invention relates to functional red fluorescent proteins that are designed to have improved brightness, reduced spectral cross talk and to be rapidly and efficiently expressed in mammalian cells. Functional red fluorescent proteins are well suited for multiplexed fluorescent analysis, and FRET based applications with existing *Aequorea* fluorescent proteins.

The present invention includes mutants of red fluorescent proteins with improved spectral, and biochemical properties, for use as fluorescent markers and as FRET partners. The functional red fluorescent proteins of the present invention comprise one or more key mutations designed to provide for improved folding, brightness and to create functional red fluorescent proteins that have sharper, more defined excitation and emission peaks when expressed in mammalian cells.

In one embodiment this invention provides a nucleic acid comprising a nucleotide sequence encoding a functional red fluorescent protein comprising at least one mutation corresponding to positions D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216.

In one aspect, the functional red fluorescent protein exhibits a reduced molar extinction coefficient at 487 nm compared to the wild type Anthozoan red fluorescent protein (SEQ. ID. NO. 7).

5 In one aspect, the functional red fluorescent protein exhibits a reduced molar extinction coefficient at 530 nm compared to the wild type Anthozoan red fluorescent protein (SEQ. ID. NO. 7).

In one aspect, the functional red fluorescent protein exhibits a higher molar extinction coefficient at 583 nm compared to the wild type Anthozoan red fluorescent protein (SEQ. ID. NO. 7).

10 In one aspect, the functional red fluorescent protein is brighter than the wild type Anthozoan red fluorescent protein (SEQ. ID. NO. 7) when excited at 558 nm.

In one aspect, the functional red fluorescent protein is brighter than the wild type Anthozoan red fluorescent protein (SEQ. ID. NO. 7) when expressed in a mammalian cell grown at 37 °C.

15 In another aspect, the functional red fluorescent protein exhibits a higher quantum yield compared to the wild type Anthozoan red fluorescent protein (SEQ. ID. NO. 7).

In one aspect, the functional red fluorescent protein exhibits a faster rate of autocatalytic formation compared to the wild type Anthozoan red fluorescent protein
20 (SEQ. ID. NO. 7).

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 59 in SEQ. ID. NO. 7 selected from D59S, D59A, D59H, D59E or D59P.

25 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 60 in SEQ. ID. NO. 7 selected from the group consisting of I60T, I60A, I60C, I60V and I60L.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 62 in SEQ. ID. NO. 7 selected from the group consisting of S62A, S62G, S62C and S62T.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 63 in SEQ. ID. NO. 7 selected from the group consisting of P63T, P63H, P63F and P63W.

5 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 64 in SEQ. ID. NO. 7 selected from the group consisting of Q64K, Q64P, Q64T, Q64N and Q64R.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 65 in SEQ. ID. NO. 7 selected from the group consisting of F65L, F65V, F65I, F65M, F65Y and F65W.

10 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 66 in SEQ. ID. NO. 7 selected from the group consisting of Q66R, Q66R, Q66P, Q66K, Q66E, Q66T, Q66A and Q66G.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 69 in SEQ. ID. NO. 7 selected from the group
15 consisting of S69L, S69A, S69V and S69T.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 70 in SEQ. ID. NO. 7 selected from the group consisting of K70M, K70Q, K70L and K70R.

In one embodiment, the functional red fluorescent protein comprises at least
20 one mutation corresponding to position 71 in SEQ. ID. NO. 7 selected from the group consisting of V71C, V71L, V71A and V71I.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 72 in SEQ. ID. NO. 7 selected from the group consisting of Y72F and Y72W.

25 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 73 in SEQ. ID. NO. 7 selected from the group consisting of V73A, V73L, V73S and V73I.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 93 in SEQ. ID. NO. 7 selected from the group
30 consisting of W93L, W93Y, W93C and W93F.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 95 in SEQ. ID. NO. 7 selected from the group consisting of R95K.

5 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 98 in SEQ. ID. NO. 7 selected from the group consisting of N98T, N98D, N98A and N98Q.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 143 in SEQ. ID. NO. 7 selected from the group consisting of W143L, W143F, W143C, W143Y and W143L.

10 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 145 in SEQ. ID. NO. 7 selected from the group consisting of A145P, A145S, A145G and A145L.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 146 in SEQ. ID. NO. 7 selected from the
15 group consisting of S146R, S146G, S146N, S146H, S146T, S146A and S146D.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 147 in SEQ. ID. NO. 7 selected from the group consisting of T147N, T147K and T147S.

In one embodiment, the functional red fluorescent protein comprises at least
20 one mutation corresponding to position 148 in SEQ. ID. NO. 7 selected from the group consisting of E148V and E148D.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 151 in SEQ. ID. NO. 7 selected from the group consisting of Y151F, Y151N, Y151D, Y151S, Y151T and Y151A.

25 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 159 in SEQ. ID. NO. 7 selected from the group consisting of G159A, G159S and G159V.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 161 in SEQ. ID. NO. 7 selected from the
30 group consisting of I161V, I161V, I161F, I161M and I161L

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 163 in SEQ. ID. NO. 7 selected from the group consisting of K163I, K163R, K163T, K163E, K163V, K163G and K163A.

5 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 171 in SEQ. ID. NO. 7 selected from the group consisting of G171S and G171A.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 179 in SEQ. ID. NO. 7 selected from the group consisting of S179A, S179P, S179T, S179E, S179Q and S179K.

10 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 181 in SEQ. ID. NO. 7 selected from the group consisting of Y181F, Y181W, Y181N and Y181I.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 197 in SEQ. ID. NO. 7 selected from the
15 group consisting of S197Y, S197T, S197N and S197A.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 199 in SEQ. ID. NO. 7 selected from the group consisting of L199I, L199V, L199I and L199A.

In one embodiment, the functional red fluorescent protein comprises at least
20 one mutation corresponding to position 214 in SEQ. ID. NO. 7 selected from the group consisting of Y214F, Y214H and Y214L.

In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 215 in SEQ. ID. NO. 7 selected from the group consisting of E215G, E215Q and E215R.

25 In one embodiment, the functional red fluorescent protein comprises at least one mutation corresponding to position 216 in SEQ. ID. NO. 7 selected from the group consisting of R216K, R216L, R216C and R216F.

In one embodiment the invention comprises an expression vector, comprising; expression control sequences operatively linked to a nucleic acid molecule encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution corresponding to position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216.

In another embodiment, the invention includes a recombinant host cell, comprising; a nucleic acid molecule encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution corresponding to position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216.

In yet another embodiment, the invention comprises a functional fluorescent protein, comprising; an amino acid sequence that differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution corresponding to position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216.

In another aspect the invention includes a fusion protein, comprising; a protein of interest operably coupled to a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution corresponding to position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216.

In one embodiment the invention includes a transgenic organism, comprising; a nucleic acid molecule encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution corresponding to position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145,

S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216.

In another aspect, the invention includes a method for identifying a protein – protein interaction, comprising;

- 5 a) providing a population of cells comprising,
 a functional red fluorescent protein whose sequence differs from the
 amino acid sequence of an Anthozoan red fluorescent protein (SEQ.
 ID. NO. 7) by at least one amino acid substitution corresponding to
10 position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72,
 V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159,
 I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216,
 wherein said functional red fluorescent protein is operably coupled to a
 first protein of interest,
- 15 b) introducing a library of test proteins of interest operably coupled to
 a functional green fluorescent protein into said population of cells,
 wherein said functional green fluorescent protein and said
 functional red fluorescent protein can undergo fluorescence
 energy transfer (FRET), and
 wherein each member of said population of cells receives on
20 average one member of said library of test proteins of interest
 operably coupled to said functional green fluorescent protein,
- c) screening said population of cells for FRET between said functional
 green fluorescent protein and said functional red fluorescent protein,
 and
- 25 d) comparing the FRET in step c) to the FRET in a control cell in the
 absence of said library of test proteins of interest operably coupled to
 said functional green fluorescent protein.

In another embodiment, the invention includes a method for identifying a modulator of protein – protein interactions, comprising;

- 30 a) contacting a cell with a test chemical, wherein said cell comprises,

- 5 i) a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution corresponding to position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216, wherein said functional red fluorescent protein is operably coupled to a first protein of interest,
- 10 ii) a functional green fluorescent protein, wherein said functional green fluorescent protein is operably coupled to a second protein of interest, and wherein said functional green fluorescent protein and said functional red fluorescent protein undergo fluorescence energy transfer (FRET) when said first
- 15 operably coupled protein of interest and said second operably protein of interest associate,
- b) detecting FRET between said functional green fluorescent protein and said functional red fluorescent protein in the presence of said test chemical, and
- 20 c) comparing the FRET in step b) to the FRET in a control cell in the absence of said test chemical.

25 In one aspect of this method, the method further comprises the step of contacting the cell with an activator prior to the addition of the test chemical. In another aspect the method further includes the step of detecting the viability of the cell.

In another embodiment the invention includes a test chemical and a pharmaceutical composition comprising a test chemical identified by the methods described herein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 Shows the mammalianized RFP created to provide for optimal codon usage and translational initiation in mammalian cells. Restriction sites, for insertion of mutagenic oligonucleotides, are shown above the sequence.

FIG. 2. Shows the retroviral mammalian expression vector ABSC258. In this construct high-level mammalian expression is achieved via the strong viral CMV promoter.

10

FIG. 3. Shows the result of flow cytometry analysis of wild type and RFP expressing NIH3T6 cells.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

15

Definitions

The techniques and procedures are generally performed according to conventional methods in the art and various general references. (Lakowicz, J.R. Topics in Fluorescence Spectroscopy, (3 volumes) New York: Plenum Press (1991), and Lakowicz, J. R. (1996) Scanning Microsc Suppl. 10 213-24, for fluorescence techniques; Sambrook *et al.* (1989) Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., for molecular biology methods; Cells: A Laboratory Manual, 1st edition (1998) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., for cell biology methods; Optics Guide 5 Melles Griot® Irvine CA, and Optical Waveguide Theory, Snyder & Love published by Chapman & Hall for general optical methods, which are incorporated herein by reference).

“Activity” refers to the enzymatic or non-enzymatic activity capable of modifying an amino acid residue or peptide bond (preferably enzymatic). Such covalent modifications include proteolysis, phosphorylation, dephosphorylation, glycosylation, methylation, sulfation, prenylation and ADP-ribsoylation. The term includes non-covalent modifications including protein-protein interactions, and the

30

binding of allosteric, or other modulators or second messengers such as calcium, or cAMP or inositol phosphates to a polypeptide.

Amino acid "substitutions" are defined as one for one amino acid replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

Amino acid "insertions" or "deletions" are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. The variation allowed in a particular amino acid sequence may be experimentally determined by producing the peptide synthetically or by systematically making insertions, deletions, or substitutions of nucleotides in the gene sequence using recombinant DNA techniques.

"Animal" as used herein may be defined to include human, domestic (cats, dogs, etc), agricultural (cows, horses, sheep, goats, chicken, fish, etc) or test species (frogs, mice, rats, rabbits, simians, etc).

"Chimeric" molecules are polynucleotides or polypeptides which are created by combining one or more nucleotide sequences of this invention (or their parts) with additional nucleic acid sequence(s). Such combined sequences may be introduced into an appropriate vector and expressed to give rise to a chimeric polypeptide which may be expected to be different from the native molecule in one or more of the following characteristics: cellular location, distribution, ligand- binding affinities, interchain affinities, degradation/turnover rate, signaling, etc.

The terms "cleavage site" or "protease site" refers to the bond cleaved by the protease (e.g. a scissile bond) and typically the surrounding three to four amino acids of either side of the bond.

"Control elements" or "regulatory sequences" are those non-translated regions of the gene or DNA such as enhancers, promoters, introns and 3' untranslated regions which interact with cellular proteins to carry out replication, transcription, and translation. They may occur as boundary sequences or even split the gene. They function at the molecular level and along with regulatory genes are very important in development, growth, differentiation and aging processes.

"Corresponds to" refers to a polynucleotide sequence that is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to all or a portion of a reference polypeptide sequence. In contradistinction, the term "complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA".

"Derivative" refers to those polypeptides which have been chemically modified by such techniques as ubiquitination, labeling, pegylation (derivatization with polyethylene glycol), and chemical insertion or substitution of amino acids such as ornithine which do not normally occur in human proteins.

The term "engineered protease site" refers to a protease site that has been modified from the naturally existing sequence by at least one amino acid substitution.

The term "fluorescent property" refers to any one of the following, the molar extinction coefficient at an appropriate excitation wavelength, the fluorescent quantum efficiency, the shape of the excitation or emission spectrum, the excitation wavelength maximum, or the emission magnitude at any wavelength during, or at one or more times after excitation of the fluorescent moiety, the ratio of excitation amplitudes at two different wavelengths, the ratio of emission amplitudes at two different wavelengths, the excited state lifetime, the fluorescent anisotropy or any other measurable property of a fluorescent moiety and the like. Preferably fluorescent property refers to fluorescence emission, or the fluorescence emission ratio at two or more wavelengths.

The term "homolog" refers to two sequences or parts thereof, that are greater than, or equal to 85% identical when optimally aligned using the ALIGN program. Homology or sequence identity refers to the following. Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably,

two protein sequences (or polypeptide sequences derived from them of at least 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, 5 (1972) in Atlas of Protein Sequence and Structure 5, National Biomedical Research Foundation, 101-110, and Supplement 2 to this volume, pp. 1-10.

An "inhibitor" is a substance that retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, antagonists and their derivatives.

10 "Isolated" refers to material removed from its original environment (e.g. the natural environment if it is naturally occurring), and thus is altered from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original 15 environment of the polynucleotide.

The term "linker" or "linker moiety" refers to an amino acid, polypeptide or protein sequence that serves to operatively couple a fluorescent protein to a protein of interest or second fluorescent protein. Linkers typically comprise a single polypeptide chain that covalently couples the fluorescent protein to the protein of interest or 20 second fluorescent protein. Linkers may be of any size.

The term "modulates" refers to, either the partial or complete, enhancement or inhibition (e.g. attenuation of the rate or efficiency) of an activity or process.

The term "modulator" refers to a chemical compound (naturally occurring or non-naturally occurring), such as a biological macromolecule (e.g., nucleic acid, 25 protein, non-peptide, or organic molecule), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian, including human) cells or tissues. Modulators are evaluated for potential activity as inhibitors or activators (directly or indirectly) of a biological process or processes (e.g., agonist, partial antagonist, partial agonist, inverse agonist, antagonist, antineoplastic agents, 30 cytotoxic agents, inhibitors of neoplastic transformation or cell proliferation, cell proliferation-promoting agents, and the like) by inclusion in screening assays

described herein. The activity of a modulator may be known, unknown or partially known.

“Naturally fluorescent protein” refers to proteins capable of forming a highly fluorescent, intrinsic chromophore either through the cyclization and oxidation of internal amino acids within the protein or via the enzymatic addition of a fluorescent
5 co-factor. Typically such chromophores can be spectrally resolved from weakly fluorescent amino acids such as tryptophan and tyrosine.

An "oligonucleotide" or "oligomer" is a stretch of nucleotide residues which has a sufficient number of bases to be used in a polymerase chain reaction (PCR), a
10 site directed mutagenesis reaction or a cassette to create a desired sequence element. These short sequences are based on (or designed from) genomic or cDNA sequences and are used to amplify, mutate or create particular sequence elements. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 50 nucleotides, preferably about 15 to 30
15 nucleotides. They are chemically synthesized and may also be used as probes.

An "oligopeptide" is a short stretch of amino acid residues and may be expressed from an oligonucleotide. It may be functionally equivalent to and either the same length as or considerably shorter than a "fragment", "portion", or "segment" of a polypeptide. Such sequences comprise a stretch of amino acid residues of at least
20 about 5 amino acids and often about 17 or more amino acids, typically at least about 9 to 13 amino acids, and of sufficient length to display biologic and/or immunogenic activity.

The term "operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended
25 manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

The term "operably coupled" refers to a juxtaposition wherein the components so described are either directly or indirectly coupled. Examples of directly coupled
30 components include proteins that are translationally fused together. Examples of indirectly coupled components include proteins that can functionally associate either transiently, or persistently, through a binding interaction.

The term "polynucleotide" refers to a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides. Modified forms and analogs of either type of nucleotide are also included, as are ribonucleotides or deoxynucleotides linked via novel bonds such as those described in U.S. Patent No. 5,532,130, European Patent Applications EP 0 839 830, EP 0 742 287, EP 0 285 057 and EP 0 694 559. The term includes single and double stranded forms of nucleotides, or a mixture of single and double stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine, as well as other chemical or enzymatic modifications.

The term "polypeptide" refers to amino acids joined to each other by peptide bonds or modified peptide bonds, i.e. peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Modification include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pergylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to protein such as arginylation. (See Proteins- Structure and Molecular Properties 2nd Ed., T.E. Creighton, W.H. Freeman and Company, New York (1993);

Posttranslational Covalent Modification of Proteins, B.C. Johnson, Ed., Academic Pres, New York, pp. 1-12 (1983).

A "portion" or "fragment" of a polynucleotide or nucleic acid comprises all or any part of the nucleotide sequence having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb which can be used as a probe. Such probes may be labeled with reporter molecules using nick translation, Klenow fill-in reaction, PCR or other methods well known in the art. After pretesting to optimize reaction conditions and to eliminate false positives, nucleic acid probes may be used in Southern, northern or in situ hybridizations to determine whether DNA or RNA encoding the protein is present in a biological sample, cell type, tissue, organ or organism.

"Probes" are nucleic acid sequences of variable length, preferably between at least about 10 and as many as about 6,000 nucleotides, depending on use. They are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are usually obtained from a natural or recombinant source, are highly specific and much slower to hybridize than oligomers. They may be single- or double-stranded and carefully designed to have specificity in PCR, hybridization membrane-based, or ELISA-like technologies.

The term "recognition motif" refers to all or part of a polypeptide sequence recognized by a post-translational modification activity to enable a polypeptide to become modified by that post-translational modification activity. Typically, the affinity of a protein, e.g. enzyme, for the recognition motif is about 1 mM (apparent K_d), preferably a greater affinity of about 10 μ M, more preferably, 1 μ M or most preferably has an apparent K_d of about 0.1 μ M. The term is not meant to be limited to optimal or preferred recognition motifs, but encompasses all sequences that can specifically confer substrate recognition to a peptide. In some embodiments the recognition motif is a phosphorylated recognition motif (e.g. includes a phosphate group), or comprises other post-translationally modified residues.

"Recombinant nucleotide variants" are polynucleotides that encode a protein. They may be synthesized by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce specific restriction sites or codon usage-specific mutations, may be introduced to optimize

cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic host system, respectively.

"Recombinant polypeptide variant" refers to any polypeptide which differs from a naturally occurring polypeptide by amino acid insertions, deletions and/or substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing characteristics of interest may be found by comparing the sequence of a polypeptide with that of related polypeptides and minimizing the number of amino acid sequence changes made in highly conserved regions.

10 A "signal or leader sequence" is a short amino acid sequence which is or can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.

A "standard" is a quantitative or qualitative measurement for comparison. Preferably, it is based on a statistically appropriate number of samples and is created to use as a basis of comparison when performing diagnostic assays, running clinical trials, or following patient treatment profiles. The samples of a particular standard may be normal or similarly abnormal.

The term "stringent hybridization conditions", refers to an overnight incubation at 42 °C in a solution comprising 50 % formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulfate and 20 µg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 °C. Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lower stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 °C in a solution comprising 6x SSPE (20X SSPE=3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30 % formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50 °C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes

performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC). Variation in the above conditions may be accomplished through the inclusion and / or substitution of alternative blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include

5 Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility. A polynucleotide which hybridizes only to polyA⁺ sequences (such as any 3' terminal polyA⁺ tract of a cDNA shown in the

10 sequence listing), or to a complementary stretch of T (or U) residues would not be included in the definition of a "polynucleotide" since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch, or the complement thereof.

The term "target" refers to a biochemical entity involved in a biological

15 process. Targets are typically proteins that play a useful role in the physiology or biology of an organism. A therapeutic chemical binds to a target to alter or modulate its function. As used herein, targets can include cell surface receptors, G-proteins, kinases, ion channels, phospholipases, proteases and other proteins mentioned herein.

The term "test chemical" refers to a chemical to be tested by one or more

20 screening method(s) of the invention as a putative modulator. A test chemical can be any chemical, such as an inorganic chemical, an organic chemical, a protein, a peptide, a carbohydrate, a lipid, or a combination thereof. Usually, various predetermined concentrations of test chemicals are used for screening, such as 0.01 micromolar, 1 micromolar and 10 micromolar. Test chemical controls can include the

25 measurement of a signal in the absence of the test compound or comparison to a compound known to modulate the target.

The term "transgenic" is used to describe an organism that includes exogenous genetic material within all of its cells. The term includes any organism whose genome has been altered by *in vitro* manipulation of the early embryo or fertilized egg or by any

30 transgenic technology to induce a specific gene knockout.

The term "transgene" refers any piece of DNA which is inserted by artifice into a cell, and becomes part of the genome of the organism (*i.e.*, either stably

integrated or as a stable extrachromosomal element) which develops from that cell. Such a transgene may include a gene which is partly or entirely heterologous (*i.e.*, foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism. Included within this definition is a transgene
5 created by the providing of an RNA sequence that is transcribed into DNA and then incorporated into the genome. The transgenes of the invention include DNA sequences that encode the functional red fluorescent proteins that may be expressed in a transgenic non-human animal.

The following terms are used to describe the sequence relationships between
10 two or more polynucleotides: "reference sequence", "comparison window", "sequence identity", "percentage identical to a sequence", and "substantial identity". A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or may comprise a complete cDNA or gene sequence.
15 Generally, a reference sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides in length, and often at least 50 nucleotides in length. Since two polynucleotides may each (1) comprise a sequence (*i.e.*, a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) may further comprise a sequence that is divergent between the two polynucleotides,
20 sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window", as used herein, refers to a conceptual segment of at least 20 contiguous nucleotide positions wherein a polynucleotide sequence may be compared to a reference
25 sequence of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may
30 be conducted by the local homology algorithm of Smith and Waterman (1981) *Adv. Appl. Math.* 2: 482, by the homology alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48: 443, by the search for similarity method of Pearson and

Lipman (1988) Proc. Natl. Acad. Sci. (U.S.A.) 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection, and the best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by the various methods selected. The term "sequence identity" means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term "percentage identical to a sequence" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 30 percent sequence identity, preferably at least 50 to 60 percent sequence identity, more usually at least 60 percent sequence identity as compared to a reference sequence over a comparison window of at least 20 nucleotide positions, frequently over a window of at least 25-50 nucleotides, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the polynucleotide sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the window of comparison.

As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 30 percent sequence identity, preferably at least 40 percent sequence identity, more preferably at least 50 percent sequence identity, and most preferably at least 60 percent sequence identity. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of

amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic-aspartic, and asparagine-glutamine.

Since the list of technical and scientific terms cannot be all encompassing, any undefined terms shall be construed to have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. Furthermore, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. For example, reference to a "restriction enzyme" or a "high fidelity enzyme" may include mixtures of such enzymes and any other enzymes fitting the stated criteria, or reference to the method includes reference to one or more methods for obtaining cDNA sequences which will be known to those skilled in the art or will become known to them upon reading this specification.

Before the present sequences, variants, formulations and methods for making and using the invention are described, it is to be understood that the invention is not to be limited only to the particular sequences, variants, formulations or methods described. The sequences, variants, formulations and methodologies may vary, and the terminology used herein is for the purpose of describing particular embodiments. The terminology and definitions are not intended to be limiting since the scope of protection will ultimately depend upon the claims.

25

I. RED FLUORESCENT PROTEINS

Anthozoan fluorescent proteins (SEQ. ID. NOs 1 to 7) isolated from various species of coral display a range of fluorescence properties (**Table 2**) ranging from green fluorescent to red fluorescent emission. Compared to *Aequorea victoria* GFP, the Anthozoan fluorescent proteins exhibit overall sequence identities of between 26 to 30 % identity.

TABLE 2					
Anthozoa Fluorescent Proteins					
Species	Protein Name	Quantum Yield (Φ) & Molar Extinction (ϵ)	Excitation & Emission Max	Relative Brightness	SEQ. ID. NO.:
<i>Anemonia majano</i>	amFP486	$\Phi = 0.24$ $\epsilon = 40,000$	458 486	0.43	SEQ. ID. NO.: 1
<i>Zoanthus sp</i>	zFP506	$\Phi = 0.63$ $\epsilon = 35,600$	496, 506	1.02	SEQ. ID. NO.:2
	zFP538	$\Phi = 0.42$ $\epsilon = 20,200$	528, 538	0.38	SEQ. ID. NO.:3
<i>Discosoma striata</i>	dsFP483	$\Phi = 0.46$ $\epsilon = 23,900$	443 483	0.5	SEQ. ID. NO.:4
<i>Discosoma sp</i> "red"	drFP583	$\Phi = 0.23$ $\epsilon = 22,500$	558 583	0.24	SEQ. ID. NO.:5
<i>Clavularia sp</i>	CFP484	$\Phi = 0.48$ $\epsilon = 35,300$	456 484	0.77	SEQ. ID. NO.:6

5 In spite of the relatively low sequence identity, the alignment of the Anthozoan and *Aequorea* fluorescent proteins is consistent with the possibility that both types of protein share a common overall structural orientation and protein fold. A comparison of the sequences reveals a tendency for amino acids to alternate between hydrophobic and hydrophilic residues along β -strands, and for the conservation of
10 buried hydrophobic core residues, as well as turn motifs.

Compared to *Aequorea* GFP, the red Anthozoan fluorescent proteins have relatively low quantum yields and molar extinction coefficients resulting in proteins that exhibit an overall brightness of approximately one quarter of that of wild type *Aequorea* GFP. The broad excitation and emission spectra of the wild type red
15 fluorescent proteins makes it difficult to selectively excite or observe the proteins for multiplexed analysis or FRET applications.

II. DESIGN OF FUNCTIONAL RED FLUORESCENT PROTEIN MUTANTS

To design improved mutants of the Anthozoan red fluorescent proteins a synthetic protein (SEQ. ID. NO. 8 (nucleotide sequence), & SEQ. ID. NO. 9 (amino acid sequence) was constructed which provided for the ability to clone in a series of oligonucleotides containing randomized nucleic acid sequences at key positions in the red fluorescent protein (**FIG.1**).

In order to produce functional red fluorescent proteins capable of high level expression in mammalian cells, a synthetic gene encoding the coding region was produced. This sequence contained an additional amino acid (valine) after the start methionine to provide for an optimal Kozak sequence and high level translational initiation. The synthetic red fluorescent protein (SEQ. ID. NO. 9) was constructed by systematically replacing the wild-type codons with codons most frequently used in highly expressed human genes (see U.S. Patent No. 5,795,737, issued August 18, 1998). This synthetic gene was assembled from chemically synthesized oligonucleotides of 70 to 100 bases in length using standard molecular biology methodology. Single stranded oligonucleotide pools were PCR amplified before cloning, and the PCR products purified in agarose gels and used as templates in the next PCR step. Two adjacent fragments were then co-amplified via the use of overlapping sequences at the end of either fragment to build larger fragments. These fragments which were between 350 and 400 bp in size, were sequentially subcloned to assemble the entire gene, **FIG 1**. (Synthetic Genetics, San Diego California) The synthetic gene (SEQ. ID. NO. 9) was then sequenced, and subcloned into the retroviral expression vector ABSC258 (**FIG. 2**).

Retroviral expression vectors provide for highly efficient gene transfer to mammalian cells and stable long-term expression. These characteristics are important to ensure that libraries of mutant red fluorescent proteins can be efficiently introduced into mammalian cells and subsequently analyzed and sequenced.

Mutagenesis of the synthetic gene was completed by sub-cloning mutagenic double stranded oligonucleotide sequences into the synthetic gene (SEQ. ID. NO. 9). These oligonucleotides enabled defined regions of the protein to be targeted for mutagenesis enabling the conservation of the overall structural framework of the protein to remain intact. These oligonucleotides (**Table 3**) were designed to be

cassetted into the engineered restriction sites incorporated during synthesis of the synthetic gene.

TABLE 3

Relative position in GFP	drFP58 3	dsFP48 3, GFP	Degenerate codon bp Upper case indicates 90% probability, lower case indicates 10 % probability			1st row = Amino acids generated from the selected degenerate codon 2nd row = Codon used 3 rd row = Probability							
58	D59	H, P	G	A	C	D	A	H	P				
			c	c		GAC	GcG	Cac	ccC				
						0.81	0.09	0.09	0.01				
59	I60	T	A	T	C	I	T						
				c		ATC	AcC						
						0.9	0.1						
61	S62	C, V	A	G	C	S	C						
			t			AGC	Tgc						
						0.9	0.1						
62	P63	T	C	C	C	P	T						
			a			CCC	Acc						
						0.9	0.1						
63	Q64	T	C	A	G	Q	K	P	T				
			a	c		CAG	AaG	CgG	acG				
						0.81	0.09	0.09	0.01				
64	F65	L	T	T	C	F	V	I	L				
			a, g		g	TTC	gTg, gTC	Atc	TTg				
						0.72	0.1	0.09	0.08				
65	Q66	S	C	A	G	Q	R	P	K	E	T	A	G
			a, g	c, g		CAG	CgC, agG	CcG	Aag	Ga g	acG	gc G	ggG
						0.64	0.09	0.08	0.08	0.08	0.08	0.01	0.01
68	S69	N, V, L	T	C	G	S	L	A	V				
			g	t		TCG	TtG	gCG	gtG				
						0.81	0.09	0.09	0.01				

69	K70	Q, M	A	A	G	K	M	Q	L				
			c	t		AAG	AtG	cAG	ctG				
						0.81	0.09	0.09	0.01				
70	V71	A, C	G	T	C	V	C						
				c		GTC	GcC						
						0.9	0.1						
71	Y72	F	T	A	C	Y	F						
				t		TAC	TtC						
						0.9	0.1						
72	V73	S, A	G	T	G	V	A	L	S				
			t	c		GTG	GcG	tTG	tcG				
						0.81	0.09	0.09	0.01				
Second Mutagenic Section													
94	W93	Q	T	G	G	W	L	C	F				
				t	c	TGG	TtG	TGc	Ttc				
						0.81	0.09	0.09	0.01				
96	R95	K	A	G	G	R	K						
				a		AGG	AaG						
						0.9	0.1						
99	N98	H, F, S	A	A	C	N	T	D	A				
			g	c		AAC	AcC	gAC	gcC				
						0.81	0.09	0.09	0.01				
Third Mutagenic Section													
145	W143	Y, F	T	G	G	W	L	C	F				
				t	c	TGG	TtG	TGc	Ttc				
						0.81	0.09	0.09	0.01				
147	A145	S, P	G	C	C	A	P	S					
			c, t			GCC	cCC	tCC					
						0.8	0.1	0.1					
148	S146	H, G	A	G	C	S	R	G	N	H	D		
			c, g	a		AGC	cGC	gGC	AaC	caC	gaC		
						0.72	0.09	0.09	0.08	0.01	0.01		

149	T147	N, K	A	C	C	T	N	K					
				a	G	ACC, ACG	AaC	AaG					
						0.9	0.05	0.05					
150	E148	V	G	A	G	E	V						
				t		GAG	GtG						
						0.9	0.1						
153	Y151	M, T	T	A	C	Y	N	D	S	T	A		
			a, g	c		TAC	aAC	gAC	TcC	acC	gcC		
						0.72	0.09	0.09	0.08	0.0 1	0.0 1		
Fourth Mutagenic Section													
163	G159	V, A	G	G	C	G	A	V					
				c, t		GGC	GcC	GtC					
						0.8	0.1	0.1					
165	I161	F	A	T	C	I	V	F	M	L			
			t, g		g	ATC	gTC, gTg	tTC	ATg	tTg			
						0.72	0.1	0.09	0.08	0.0 1			
167	K163	I, T, V	A	A	A	K	I	R	T	E	V	G	A
			g	t, g, c		AAA	AtA	Ag A	AcA	gA A	gtA	gg A	gcA
						0.63	0.09	0.09	0.09	0.0 7	0.0 1	0.0 1	0.01
175	G171	S	G	G	C	G	S						
			a			GGC	aGC						
						0.9	0.1						
Fifth Mutagenic Section													
183	S179	Q	T	C	A	S	A	P	T	sto p	E	Q	K
			g, c, a	a		TCA	gCA	cCA	aCA	Ta A	ga A	caA	aaa
						0.63	0.09	0.09	0.09	0.0 7	0.0 1	0.0 1	0.01

185	Y181	N	T	A	C	Y	F	N	I				
			a	t		TAC	TtC	AaC	atC				
						0.81	0.09	0.09	0.01				
Sixth Mutagenic Section													
203	S197	T, Y	T	C	C	S	Y	T	N				
			a	a		TCC	TaC	aCC	aaC				
						0.81	0.09	0.09	0.01				
Seventh Mutagenic Section													
205	L199	S	T	T	G	L	S						
				c		TTG	TcG						
						0.9	0.1						
Seventh Mutagenic Section													
221	Y214	L, H	T	A	C	Y	F	H	L				
			c	t		TAC	TtC	cAC	ctC				
						0.81	0.09	0.09	0.01				
Seventh Mutagenic Section													
222	E215	Q, G	G	A	G	E	G	Q	R				
			c	g		GAG	GgG	cAG	cgG				
						0.81	0.09	0.09	0.01				
Seventh Mutagenic Section													
223	R216	F	C	G	C	R	L	C	F				
			t	t		CGC	CtC	tGC	ttC				
						0.81	0.09	0.09	0.01				

This approach enables the controlled mutagenesis of key residues in the protein molecule, without the disruption of essential residues, that would otherwise lead to the complete loss of fluorescence. Importantly, the method enables selective control of the first, second, and third position of the codon, thereby enabling the selection of conservative mutations if desired.

To identify key residues in the red fluorescent protein, comparisons were made to known favorable mutations in *Aequorea* GFP, and divergences in the sequences between the various species of Anthozoan GFPs, and particularly the red (drFP583) (SEQ. ID. NO. 5 - nucleic acid, & SEQ. ID. NO. 7 - amino acid) and green (dsFP483) (SEQ. ID. NO. 4) fluorescent proteins from *Discosoma striata*. In Table 3, the amino acid positions refer to *Aequorea* GFP numbering. The corresponding numbering of the equivalent amino acids in the Anthozoan GFPs

To maximize the chance of identifying mutations that confer a favorable characteristic, the level of mutagenesis was designed to result in the wild type amino acid being present at each position mutagenized approximately 80% of the time. This approach (often termed soft mutagenesis) helps to avoid the creation of libraries
5 containing mostly non-functional mutants, a situation that can arise if a protein is relatively sensitive to alterations in its amino acid composition.

To ensure that the entire library of mutants was screened, the mutagenesis was completed in a systematic step by step process. This process limited the total diversity in each library to an acceptable value that could be practically screened in mammalian
10 cells via flow cytometry. For example in **Table 3**, the first mutagenic primer has a total diversity of around 1.05×10^6 , compared to the diversity of the entire library which is of the order of 3.42×10^{17} . Typical commercially available FACS instrumentation have analysis rates of around $2 - 5 \times 10^4$ cells / second, making a realistic analysis of the entire library impractical in a reasonable time frame. By
15 contrast, a screen of a library of about a million cells is relatively easily accomplished, and can, furthermore, be sorted several times over to ensure that the relatively rare, favorable mutations are identified.

III. SCREENING OF LIBRARIES

20

Once the mutagenic library of red fluorescent mutants has been subcloned into the retroviral expression vector, a library of retroviral plasmids can be produced using standard packaging cell lines, such as PT67 cells. Supernatant from these cells can then used to infect the mammalian cells in order to express the mutant fluorescent
25 proteins.

Favorable mutants from this step can be identified by FACS analysis based on their improved fluorescence characteristics and increased brightness when expressed in mammalian cells. Typically cells will be selected based on their brightness (fluorescence emission) around 583 nm when excited at around 558 nm.

30

In **FIG. 3**, flow cytometry and cell sorting were conducted using a Becton Dickinson FACSVantage™ SE with a Coherent Innova^R 70C Spectrum laser producing 60 mW of power at 530.9 nm excitation. The flow cytometer was equipped

with pulse processing and the Macrosort™ flow cell. Fluorescence emission was detected via a 585/42 nm bandpass emission filter, separated by a 560 nm short path dichroic mirror. Using the CloneCyt™ Plus integrated deposition system on the FACS Vantage™ SE, single cells were sorted into 96-well microtiter plates based on fluorescence intensity (R3) above cellular autofluorescence from a wild type control population. In FIG. 3, wild type NIH3T6 cells are shown in the upper panel, while cells transformed with the RFP expression vector ABSC258, are shown in the lower panel. The R3 region represents cells with higher levels of red fluorescence than cellular autofluorescence, and these cells were sorted into 96 well plates for further analysis. In this experiment the sort region (R3) = 0.001% of the total population in the wild type cells, and 1.40% in the RFP transformed cells.

In addition, multiple rounds of FACS analysis and sorting can be used to selectively enrich mixed pools of brighter mutants to enable the selection of the best mutants. An additional aspect of this strategy is to re-sort the fluorescent cells based on their brightness when excited at 488 nm or 530 nm. In this case one would select for cells with reduced brightness when excited at these wavelengths in order to select for mutants with narrower, sharper excitation peaks.

Another useful sort strategy is to analyze the cells relatively rapidly (i.e. within 24 hours) after transformation in order to identify functional red fluorescent proteins that exhibit more rapid autocatalytic fluorescence development.

Typically after FACS separation, individual cells, or enriched populations of cells, can be sorted into culture plates and allowed to recover for a period of about two weeks. After this period individual cell colonies are typically large enough for further analysis either by further rounds of FACS or via a 96 well plate reader. Analysis via a plate reader provides for accurate quantification and enables a determination of the relative magnitude of the excitation peaks at 487 nm, 530 nm and 558 nm in the same sample. Once colonies expressing mutants with improved characteristics are identified, the sequences of the mutants can be rapidly identified via PCR based sequencing. This can be achieved, for example, by using standard fluorescent dye terminator chemistries on a Perkin Elmer 373 or similar automated sequencer, using direct sequencing of PCR products as described by Townley *et al.*, (1997) Genome Res. 7: (3) 293-8. Methods for DNA sequencing are well known in

the art and employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE™ (US Biochemical Corp) or Taq polymerase. Methods to extend the DNA from an oligonucleotide primer annealed to the DNA template of interest have been developed for both single- and double-stranded templates. Chain termination
5 reaction products are separated using electrophoresis and detected via their incorporated, labeled precursors.

Recent improvements in mechanized reaction preparation, sequencing and analysis have permitted expansion in the number of sequences that can be determined per day. Preferably, the process is automated with machines such as the Hamilton
10 Micro Lab 2200 (Hamilton, Reno, Nev.), Peltier Thermal Cyclers (PTC200; MJ Research, Watertown Mass.) and the Applied Biosystems Catalyst 800 and 377 and 373 DNA sequencers.

The best mutants from this first round of mutagenesis may then be used as the starting product for the next round of mutagenesis. As previously described,
15 oligonucleotides containing a reasonable total diversity are selected to ensure that a complete and thorough search of all of the mutants can be rapidly completed.

After all the mutagenic steps have been completed it is possible to further enhance the fluorescence properties via the use of error prone PCR or Ping pong mutagenesis approaches using methods known in the art to create a highly optimized
20 red fluorescent protein.

Another mutagenesis step may then be completed by recombining the entire pool of favorable mutants to select the most favorable combinations. In this approach the probability of mutagenesis at each position is approximately 50 %, and all the mutations have an equal probability of incorporation into the template fluorescent
25 protein. The most favorable combinations of mutations are then selected to provide for the greatest improvements in brightness and fluorescent properties.

IV. USE AS A MARKER OF GENE EXPRESSION AND CELL MOVEMENT

30 Typically the functional red fluorescent proteins of the present invention will be introduced and expressed in target cells via the use of standard molecular biology techniques known in the art.

For cell movement studies, expression of the red fluorescent protein will generally be driven via a cell-type specific promoter, in order to be able to selectively monitor the movement of the target cell type. In some cases, for example in cell mixing experiments, it will be preferred for expression to be driven via a constitutive promoter, in other cases it may be preferable to drive expression from an inducible, or developmentally regulated promoter in order to monitor cellular differentiation.

In another embodiment it may be desirable to include additional spectrally resolved fluorescent proteins to simultaneously track both cell movement and differentiation in order to determine both when and where gene expression is modulated. In both cases, nucleic acids in the form of an expression vector including expression control sequences operatively linked to a nucleotide sequence coding for expression of the red fluorescent protein will be used for introducing the proteins into cells. As used, the term "nucleotide sequence coding for expression of" a polypeptide refers to a sequence that, upon transcription and translation of mRNA, produces the polypeptide. This can include sequences containing, *e.g.*, introns. As used herein, the term "expression control sequences" refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (*i.e.*, ATG) in front of a protein-encoding gene, splicing signals for introns, IRES sequences (internal ribosome entry site) maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons.

Methods that are well known to those skilled in the art can be used to construct expression vectors containing the red fluorescent proteins. These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. (See, for example, the techniques described in Maniatis, *et al.*, (1989) Cold Spring Harbor Laboratory, N.Y.). Many commercially available expression vectors are available from a variety of sources including Clontech (Palo Alto, CA), Stratagene (San Diego, CA) and Invitrogen (San Diego, CA) as well as many other commercial sources.

A contemplated version of the method is to use inducible controlling nucleotide sequences to produce a sudden increase in the expression of the RFP construct e.g., by inducing expression of the construct. Exemplary inducible systems include the tetracycline inducible system first described by Bujard and colleagues
5 (Gossen and Bujard (1992) Proc. Natl. Acad. Sci USA 89 5547-5551, Gossen *et al.* (1995) Science 268 1766-1769) and described in U.S. Patent No 5,464,758.

Transformation of cells

Transformation of a host cell with recombinant DNA may be carried out by
10 conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells that are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl₂ method by procedures well known in the art. Alternatively, MgCl₂ or RbCl can be used. Transformation can also be performed after forming a protoplast
15 of the host cell or by electroporation.

When the host is an eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be co-transfected with DNA
20 sequences encoding the fusion polypeptide of the invention, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use an eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (*Eukaryotic Viral Vectors*, Cold Spring
25 Harbor Laboratory, Gluzman ed., 1982). Preferably, an eukaryotic host is utilized as the host cell as described herein.

V. USE AS A FUSION TAG

30 The functional red fluorescent proteins of this invention are useful to track the movement of proteins in cells. In this embodiment, a nucleic acid molecule encoding the fluorescent protein is fused in frame to a nucleic acid molecule encoding the

protein of interest in an expression vector. Upon expression inside the cell, the protein of interest can be localized based on fluorescence. Typically the protein of interest would be coupled to the RFP via a flexible linker to ensure that both the target protein and fluorescent protein functioned correctly and were efficiently folded.

5 Methods for constructing and introducing such fusion proteins are well known in the art and are also discussed above.

In another version, two or more proteins of interest are simultaneously tracked by fusing the first protein with a functional red fluorescent protein, and the second protein fused to a second fluorescent protein, such as one of the proteins listed in
10 **Table 1.** Typically the second fluorescent protein is chosen based on its fluorescent properties so that it can be spectrally resolved from the functional red fluorescent protein.

15 VI. USE IN TRANSGENIC ORGANISMS

In one embodiment, the invention provides a transgenic non-human organism that expresses a nucleic acid sequence that encodes a functional red fluorescent protein. Because such constructs can be expressed within intact living organisms without the need to add co-factors or reagents, and the red emission passes well
20 through tissues, the red fluorescent proteins enable the monitoring of cell movement and differentiation within the entire, intact, living organism.

In another embodiment, the invention can be used to identify where in specific tissues a particular cell type is located, for example, by expression of a red fluorescent protein from a tissue or cell type specific promoter. In another embodiment it may be
25 desirable to include additional spectrally resolved fluorescent proteins to simultaneously track both cell movement and differentiation in order to determine both when and where gene expression is modulated. Such non-human organisms include vertebrates such as rodents, fish such as Zebrafish, non-human primates and reptiles as well as invertebrates. Preferred non-human organisms are selected from
30 the rodent family including rat and mouse, most preferably mouse. The transgenic non-human organisms of the invention are produced by introducing transgenes into the germline of the non-human organism. Embryonic target cells at various

developmental stages can be used to introduce transgenes. Different methods are used depending on the organism and stage of development of the embryonic target cell. In vertebrates, the zygote is the best target for microinjection. In the mouse, the male pronucleus reaches the size of approximately 20 micrometers in diameter, which
5 allows reproducible injection of 1-2 pl of DNA solution. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated into the host genome before the first cleavage (Brinster *et al.*, (1985) Proc. Natl. Acad. Sci. USA 82 4438-4442.). As a consequence, all cells of the transgenic non-human animal will carry the incorporated transgene. This will in general also be
10 reflected in the efficient transmission of the transgene to offspring of the founder since 50% of the germ cells will harbor the transgene. Microinjection of zygotes is the preferred method for incorporating transgenes in practicing the invention.

A transgenic organism can be produced by cross-breeding two chimeric organisms which include exogenous genetic material within cells used in
15 reproduction. Twenty-five percent of the resulting offspring will be transgenic *i.e.*, organisms that include the exogenous genetic material within all of their cells in both alleles. 50% of the resulting organisms will include the exogenous genetic material within one allele and 25% will include no exogenous genetic material.

Retroviral infection can also be used to introduce transgene into a non-human
20 organism. In vertebrates, the developing non-human embryo can be cultured *in vitro* to the blastocyst stage. During this time, the blastomeres can be targets for retro viral infection (Jaenich, R., (1976) Proc. Natl. Acad. Sci USA 73 1260-1264.). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Hogan, *et al.* (1986) in Manipulating the Mouse Embryo, Cold Spring
25 Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The viral vector system used to introduce the transgene is typically a replication-defective retrovirus carrying the transgene (Jahner, *et al.*, (1985) Proc. Natl. Acad. Sci. USA 82 6927-6931; Van der Putten, *et al.*, (1985) Proc. Natl. Acad. Sci USA 82 6148-6152). Transfection is easily and efficiently obtained by culturing the blastomeres on a monolayer of
30 virus-producing cells (Van der Putten, *supra*; Stewart, *et al.*, (1987) EMBO J. 6 383-388).

Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (D. Jahner *et al.*, (1982) Nature 298 623-628). Most of the founders will be mosaic for the transgene since incorporation occurs only in a subset of the cells that formed the transgenic nonhuman animal. Further, the founder may contain various retro viral insertions of the transgene at different positions in the genome that generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germ line, albeit with low efficiency, by intrauterine retroviral infection of the midgestation embryo (D. Jahner *et al.*, *supra*). A third type of target cell for transgene introduction for vertebrates is the embryonic stem cell (ES). ES cells are obtained from pre-implantation embryos cultured *in vitro* and fused with embryos (M. J. Evans *et al.* (1981) Nature 292 154-156; M.O. Bradley *et al.*, (1984) Nature 309 255-258; Gossler, *et al.*, (1986) Proc. Natl. Acad. Sci USA 83 9065-9069; and Robertson *et al.*, (1986) Nature 322 445-448). Transgenes can be efficiently introduced into the ES cells by DNA transfection or by retro virus-mediated transduction. Such transformed ES cells can thereafter be combined with blastocysts from a nonhuman animal. The ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal. (For review see Jaenisch, R., (1988) Science 240 1468-1474).

In another embodiment, the invention provides a transgenic plant that expresses a nucleic acid sequence that encodes red fluorescent protein. Because such constructs can be specifically expressed, both spatially and temporally, within intact living cells, the invention provides the ability to monitor the spatial distribution of a target cell type, within defined cell populations, tissues, or in the entire transgenic plant.

In another embodiment, the approach can be used to specifically identify where in specific tissues a particular gene is expressed, for example by expression of the RFP from tissue specific plant promoters.

In another embodiment it may be desirable to include additional spectrally resolved fluorescent proteins to simultaneously track both cell movement and differentiation in order to determine both when and where gene expression is modulated.

Transgenic plants may be produced by any one of a number of methods of plant transformation and regeneration. Numerous methods for plant transformation have been developed, including biological and physical, plant transformation protocols. See, for example, Miki et al., "Procedures for Introducing Foreign DNA
5 into Plants" in *Methods in Plant Molecular Biology and Biotechnology*, Glick, B.R. and Thompson, J.E. Eds. (CRC Press, Inc., Boca Raton, 1993) pages 67-88. In addition, expression vectors and in vitro culture methods for plant cell or tissue transformation and regeneration of plants are available. See, for example, Gruber et al., "Vectors for Plant Transformation" in *Methods in Plant Molecular Biology and
10 Biotechnology*, Glick, B.R. and Thompson, J.E. Eds. (CRC Press, Inc., Boca Raton, 1993) pages 89-119.

The most widely utilized method for introducing an expression vector into plants is based on the natural transformation system of *Agrobacterium*. See, for example, Horsch et al., (1985) *Science* 227 1229. *A. tumefaciens* and *A. rhizogenes*
15 are plant pathogenic soil bacteria which genetically transform plant cells. The Ti and Ri plasmids of *A. tumefaciens* and *A. rhizogenes*, respectively, carry genes responsible for genetic transformation of the plant. See, for example, Kado, C.I., *Crit. Rev. Plant. Sci.* 10: 1 (1991). Descriptions of *Agrobacterium* vector systems and methods for *Agrobacterium*-mediated gene transfer are provided by Gruber et al.,
20 supra, Miki et al., supra, and Moloney et al., (1989) *Plant Cell Reports* 8 238.

Despite the fact the host range for *Agrobacterium* mediated transformation is broad, some major cereal crop species and gymnosperms have generally been recalcitrant to this mode of gene transfer, even though some success has recently been achieved in rice. Hiei et al., (1994) *The Plant Journal* 6 271-282. Several methods of
25 plant transformation, collectively referred to as direct gene transfer, have been developed as an alternative to *Agrobacterium*-mediated transformation.

A generally applicable method of plant transformation is microprojectile-mediated transformation wherein DNA is carried on the surface of microprojectiles measuring 1 to 4 μm . The expression vector is introduced into plant tissues with a
30 biolistic device that accelerates the microprojectiles to speeds of 300 to 600 m/s which is sufficient to penetrate plant cell walls and membranes. Sanford et al., (1987),

Part. Sci. Technol. 5 27, Sanford, J.C., (1988) Trends Biotech. 6 299, Sanford, J.C., (1990) Physiol. Plant 79 206, Klein et al., (1992) Biotechnology 10 268.

Another method for physical delivery of DNA to plants is sonication of target cells. Zhang et al., (1991) BioTechnology 9 996. Alternatively, liposome or
 5 spheroplast fusion have been used to introduce expression vectors into plants. Deshayes et al., (1985) EMBO J., 4 2731, Christou et al., (1987) Proc Natl. Acad. Sci. U.S.A. 84 3962. Direct uptake- of DNA into protoplasts using CaCl_2 precipitation, polyvinyl alcohol or poly-Lornithine have also been reported. Hain et
 al., (1985) Mol.Gen. Genet. 199 161 and Draper et al., (1982) Plant Cell Physiol. 23
 10 451. Electroporation of protoplasts and whole cells and tissues have also been described. Donn et al., In Abstracts of VIIth International Congress on Plant Cell and Tissue Culture IAPTC, A2-38, p 53 (1990) ; D'Halluin et al., (1992) Plant Cell 4 1495-1505 and Spencer et al., (1994) Plant Mol. Biol. 24 51-61.

A preferred method is microprojectile-mediated bombardment of immature
 15 embryos. The embryos can be bombarded on the embryo axis side to target the meristem at a very early stage of development or bombarded on the scutellar side to target cells that typically form callus and somatic embryos. Targeting of the scutellum using projectile bombardment is well known to those in the art of cereal tissue culture. Klein et al., (1988) BioTechnol. , 6 559-563; Sautter et al., BiolTechnol., 9 1080-1085
 20 (1991) ; Chibbar et al., (1991) Genome, 34 435-460. The scutellar origin of regenerable callus from cereals is well known. Green et al., (1975) Crop Sci., 15 417-421; Lu et al., (1982)TAG 62 109-112; and Thomas and Scott, (1985) J. Plant Physiol. 121 159-169 - Targeting the scutellum and then using chemical selection to recover transgenic plants is well established in cereals. D/Halluin et al., Plant Cell 4:
 25 1495-1505 (1992) ; Perl et al., MGG 235: 279-284 (1992); Cristou et al., BiolTechnol. 9: 957-962 (1991).

VII. USE FOR FLUORESCENT RESONANCE ENERGY TRANSFER (FRET)

30 FRET is a general, non-destructive, spectroscopic effect that occurs under certain circumstances (see below) when two fluorophores (a donor fluorophore and acceptor fluorophore) approach closer than about 100 Å. The efficiency of FRET

between the two fluorophores is highly distant dependent, and this fact can be exploited to monitor the dynamic association of the fluorophores, or two fluorophore tagged macromolecules. By monitoring FRET between one or more fluorescent proteins it is possible to develop sensitive, non-invasive, cell based assays for a range of activities including proteolysis (see U.S. Patent No. 5,981,200 issued November 9, 1999), analyte determinations (see U.S. Patent No. 5,998,204 issued December 7, 1999) and protein – protein interactions. FRET is most readily determined by measuring the relative emissions of the donor and acceptor fluorophore and then by calculating the emission ratio of these two values. A high degree of FRET is indicated by a high value of the ratio of [acceptor emission/donor emission], and a low degree of FRET is indicated by a low value of this ratio. FRET may also may determined by measuring the degree of donor fluorescence quenching, a measurement method that has the important advantage over emission ratioing in that this value is independent of the concentration the acceptor.

The efficiency of FRET is dependent on the separation distance, the orientation of the donor and acceptor moieties, the fluorescent quantum yield of the donor moiety and the energetic overlap with the acceptor moiety. Forster derived the relationship:

$$E = (F^0 - F)/F^0 = R_0^6/(R^6 + R_0^6)$$

where E is the efficiency of FRET, F and F^0 are the fluorescence intensities of the donor in the presence and absence of the acceptor, respectively, and R is the distance between the donor and the acceptor. R_0 , the distance at which the energy transfer efficiency is 50%, is given (in Å) by

$$R_0 = 9.79 \times 10^3 (K^2 Q J n^{-4})^{1/6}$$

where K^2 is an orientation factor having an average value close to 0.67 for freely mobile donors and acceptors, Q is the quantum yield of the unquenched fluorescent donor, n is the refractive index of the intervening medium, and J is the overlap integral, which expresses in quantitative terms the degree of spectral overlap,

$$J = \int_0^\infty F_1 \lambda^4 d\lambda / \int_0^\infty F_1 d\lambda$$

where ϵ is the molar absorptivity of the acceptor in $M^{-1} \text{ cm}^{-1}$ and F_1 is the donor
5 fluorescence at wavelength λ measured in cm. The dependence of fluorescence
energy transfer on the above parameters has been reported [Forster, T. (1948)
Ann. Physik 2: 55-75; Lakowicz, J.R., Principles of Fluorescence Spectroscopy, New
York: Plenum Press (1983); Herman, B., Resonance energy transfer microscopy, in:
Fluorescence Microscopy of Living Cells in Culture, Part B, Methods in Cell Biology,
10 Vol 30, ed. Taylor, D.L. & Wang, Y.-L., San Diego: Academic Press (1989), pp. 219-
243; Turro, N.J., Modern Molecular Photochemistry, Menlo Park:
Benjamin/Cummings Publishing Co., Inc. (1978), pp. 296-361], and tables of spectral
overlap integrals are readily available to those working in the field [for example,
Berlman, I.B. Energy transfer parameters of aromatic compounds, Academic Press,
15 New York and London (1973)].

Accordingly, the functional red fluorescent proteins of the present invention
are intended to have improved brightness, reduced spectral cross talk and to be rapidly
and efficiently expressed in mammalian cells, compared to wild-type Anthozoan
proteins. Specifically such proteins are designed to exhibit reduced excitation in the
20 region 400 nm to 515 nm, where most *Aequorea* related donor fluorescent proteins are
most efficiently excited, and exhibit an improved molar extinction coefficient when
expressed in mammalian cells. Accordingly such functional red fluorescent proteins
are useful in any methods that involve FRET.

In one embodiment the functional red fluorescent proteins are useful in FRET
25 based assays for detecting protease activity in which the donor and acceptor
fluorescent proteins are separated by a cleavable linker. In this embodiment a first
fluorescent protein, for example one of the proteins in **Table 1** is selected as the
FRET donor. To optimize the efficiency and detectability of FRET within the tandem
fluorescent protein construct, several factors need to be balanced. The emission
30 spectrum of the donor moiety should overlap as much as possible with the excitation
spectrum of the acceptor moiety to maximize the overlap integral J . Also, the
quantum yield of the donor moiety and the extinction coefficient of the acceptor

should likewise be as high as possible to maximize R_0 . However, the excitation spectra of the donor and acceptor moieties should overlap as little as possible so that a wavelength region can be found at which the donor can be excited efficiently without directly exciting the acceptor. Fluorescence arising from direct excitation of the acceptor is difficult to distinguish from fluorescence arising from FRET. Similarly, the emission spectra of the donor and acceptor moieties should overlap as little as possible so that the two emissions can be clearly distinguished. High fluorescence quantum yield of the acceptor moiety is desirable if the emission from the acceptor is to be measured either as the sole readout or as part of an emission ratio. In a preferred embodiment, the donor moiety is typically excited by blue light (<500 nm) and typically emits green light (>500 nm), whereas the acceptor is efficiently excited by green, but not by blue light, and emits red light (>550 nm), for example, preferred donors include Sapphire, W1C, W1B, Emerald. Topaz is preferred for functional red fluorescent proteins that exhibit little or no direct excitation around 500 to 520 nm.

For use in measuring protease activity, the donor and acceptor fluorescent protein moieties are connected through a linker moiety. The linker moiety is preferably a peptide moiety, but can be another organic molecular moiety as well. In a preferred embodiment, the linker moiety includes a cleavage recognition site specific for an enzyme or other cleavage agent of interest. A cleavage site in the linker moiety is useful because when a tandem construct is mixed with the cleavage agent, the linker is a substrate for cleavage by the cleavage agent. Rupture of the linker moiety results in separation of the fluorescent protein moieties that is measurable as a change in FRET.

When the cleavage agent of interest is a protease, the linker can comprise a peptide containing a cleavage recognition motif for the protease. A recognition motif for a protease is a specific amino acid sequence recognized by the protease during proteolytic cleavage. The linker can contain any protease recognition motif known in the art, or discovered in the future.

In one embodiment the functional red fluorescent proteins are useful in FRET based assays for detecting the presence of an analyte (See U.S. Patent No. 5,998,204, issued December 7, 1999). In this case the linker comprising a cleavage site is replaced by a binding protein moiety. The binding protein moiety has an analyte-

binding region that binds an analyte and causes the tandem construct to change conformation upon exposure to the analyte. The donor fluorescent protein moiety is covalently coupled to the binding protein moiety. The acceptor fluorescent protein moiety, such as a functional red fluorescent protein, is covalently coupled to the binding protein moiety. In the fluorescent indicator, the donor moiety and the acceptor moiety change position relative to each other when the analyte binds to the analyte-binding region, altering fluorescence resonance energy transfer between the donor moiety and the acceptor moiety when the donor moiety is excited. The change in FRET provides an indication of the concentration of the analyte in the sample.

In another embodiment the functional red fluorescent proteins are useful for FRET based assays for detecting protein-protein interactions. This approach enables an additional range of post-translational activities to be assayed. In this embodiment, a first protein is typically covalently coupled to donor fluorescent protein (such as a fluorescent protein from **Table 1**), and a second protein is covalently coupled to the acceptor fluorescent protein (such as a functional red fluorescent protein). As previously, the donor and acceptor fluorescent proteins are selected to optimize the degree of FRET. Binding of the first protein to the second protein results in the association of the donor and acceptor fluorescent proteins resulting in an enhancement of the degree of FRET between them. This results in a measurable change in the donor and acceptor emission ratio. This approach thus enables the identification and detection of protein-protein interactions between defined proteins, as well as the ability to detect post-translational modifications that influence these protein-protein interactions.

Examples of suitable interaction domains include protein-protein interaction domains such as SH2, SH3, PDZ, 14-3-3, WW and PTB domains. Other interaction domains are described in for example, the database of interacting proteins available on the web at <http://www.doe-mbi.ucla.edu>.

To identify and characterize the interaction of two test proteins, the method would typically involve; 1) the creation of a first fusion protein comprising the first test protein coupled to the donor fluorescent protein, and a second fusion protein comprising the second test protein coupled to acceptor fluorescent protein; 2) the introduction of the test protein fusion proteins in combination into test cells, and the

donor and acceptor fluorescent proteins (without fusion proteins) into control cells; 3) the measurement of the donor and acceptor emission ratios in the control cells and test cells; and 4) comparison of the emission ratio in the control cells, compared to the emission ratio in the test cells.

5 If the cells expressing the fusion proteins exhibits an emission ratio with a significantly altered value compared to the control cells containing the fluorescent proteins alone, then the results indicate that the two proteins do interact under the experimental conditions chosen. Conversely, if the emission ratios in the control
10 cells, and in the test cells are approximately the same (after taking into account differences in relative expression of the fluorescent proteins), then the results indicate that the proteins probably don't interact strongly under the test conditions.

 The method also enables the detection and characterization of stimuli (such as receptor stimulation) that cause two proteins to alter their degree of interaction. In this case, a cell line is created that expresses the first and second fusion proteins, as
15 described above, comprising interaction domains that exhibit, or are believed to exhibit post-translational regulated interactions. For example, post-translational modification by phosphorylation of serine or threonine residues can modulate 14-3-3 domain interactions, tyrosine phosphorylation can influence SH2 domain interactions, the redox state can influence disulfide bond formation. The cell line is then exposed
20 to a test stimulus to determine whether the stimulus regulates the interaction of the two proteins. If the stimulus does regulate the interaction of the two proteins, then this will result in a modulation of the coupling of the two fluorescent proteins, subsequently resulting in a modulation of the degree of FRET and hence fluorescence emission ratio in the treated cells, compared to the non-treated cells.

25 The invention is also readily amenable to identifying new protein-protein interactions. For example, where a first protein is known, but the protein(s) with which it interacts are unknown. In this case, a first fusion protein is made between the first protein and the donor fluorescent protein (or acceptor fluorescent protein) and cloned into a suitable expression vector. Second, a library of test proteins, for
30 example isolated from a cDNA expression library, is fused in frame to the acceptor fluorescent protein (or donor fluorescent protein) and subcloned into a second expression vector. Typically the first fusion protein would be then be introduced into

a population of test cells and single clones identified that stably expressed the fusion protein. The library of test proteins (typically in the form of expression vectors) would be introduced into the clonal cells, stably expressing the first fusion protein. The resulting transformed cells would then be screened to identify cells with altered FRET compared to the control cells. Suitable clones expressing the fusion proteins with modulated FRET, (i.e., altered emission ratios) may then be identified, isolated and characterized, for example by fluorescence activated cell sorting (FACS™). To confirm that the altered emission ratio was indeed the result of FRET, and not due to alterations in the expression level of the acceptor fluorescent protein, secondary measurements of donor emission quenching in the presence and absence of the acceptor would usually be completed. This could be achieved, for example, by measuring donor emission before and after photobleaching of the acceptor. Those library members that display fusion proteins with larger relative changes in emission ratio may then be identified by the degree to which emission ratio is altered for each library member after exposure to the library of test fusion proteins.

VIII. USE FOR DRUG DISCOVERY

FRET based fluorescence assays are well suited for use with systems and methods that utilize automated and integratable workstations for identifying modulators, and chemicals having useful activity. Such systems are described generally in the art (see, U.S. Patent NOs: 4,000,976 to Kramer *et al.* (issued January 4, 1977), 5,104,621 to Pfoest *et al.* (issued April 14, 1992), 5,125,748 to Bjornson *et al.* (issued June 30, 1992), 5,139,744 to Kowalski (issued August 18, 1992), 5,206,568 Bjornson *et al.* (issued April 27, 1993), 5,350,564 to Mazza *et al.* (September 27, 1994), 5,589,351 to Harootunian (issued December 31, 1996), and PCT Application Nos: WO 93/20612 to Baxter Deutschland GMBH (published October 14, 1993), WO 96/05488 to McNeil *et al.* (published February 22, 1996), WO 93/13423 to Agong *et al.* (published July 8, 1993) and U.S. Patent No. 5,985,214, issued November 16, 1999.

Typically, such a system includes: A) a storage and retrieval module comprising storage locations for storing a plurality of chemicals in solution in

addressable chemical wells, a chemical well retriever and having programmable selection and retrieval of the addressable chemical wells and having a storage capacity for at least 100,000 addressable wells, B) a sample distribution module comprising a liquid handler to aspirate or dispense solutions from selected addressable chemical wells, the chemical distribution module having programmable selection of, and aspiration from, the selected addressable chemical wells and programmable dispensation into selected addressable sample wells (including dispensation into arrays of addressable wells with different densities of addressable wells per centimeter squared) or at locations, preferably pre-selected, on a plate, C) a sample transporter to transport the selected addressable chemical wells to the sample distribution module and optionally having programmable control of transport of the selected addressable chemical wells or locations on a plate (including adaptive routing and parallel processing), and D) a reaction module comprising either a reagent dispenser to dispense reagents into the selected addressable sample wells or locations on a plate or a fluorescent detector to detect chemical reactions in the selected addressable sample wells or locations on a plate, and a data processing and integration module.

The storage and retrieval module, the sample distribution module, and the reaction module are integrated and programmably controlled by the data processing and integration module. The storage and retrieval module, the sample distribution module, the sample transporter, the reaction module and the data processing and integration module are operably linked to facilitate rapid processing of the addressable sample wells or locations on a plate. Typically, devices of the invention can process at least 100,000 addressable wells or locations on a plate in 24 hours. This type of system is described in commonly owned U.S. Patent No. 5,985,214, issued November 16, 1999. If desired, each separate module is integrated and programmably controlled to facilitate the rapid processing of liquid samples, as well as being operably linked to facilitate the rapid processing of liquid samples. In one embodiment the system provides for a reaction module that is a fluorescence detector to monitor fluorescence. The fluorescence detector is integrated to other workstations with the data processing and integration module and operably linked with the sample transporter. Preferably, the fluorescence detector is of the type described herein and

can be used for epi-fluorescence. Other fluorescence detectors that are compatible with the data processing and integration module and the sample transporter, if operable linkage to the sample transporter is desired can be used as known in the art or developed in the future. For some embodiments of the invention, particularly for plates with 96, 192, 384 and 864 wells per plate, detectors are available for integration into the system. Such detectors are described in U.S. Patent 5,589,351 (Harootunian), U.S. Patent 5,355,215 (Schroeder), and PCT patent application WO 93/13423 (Akong). Alternatively, an entire plate may be "read" using an imager, such as a Molecular Dynamics Fluor-Imager 595 (Sunnyvale, CA). Multi-well platforms having greater than 864 wells, including 3,456 wells, can also be used in the present invention (see, for example, the PCT Application PCT/US98/11061, filed 6/2/98. These higher density well plates require miniaturized assay volumes that necessitate the use of highly sensitivity assays that do not require washing. The present invention provides such assays as described herein.

The screening methods described herein can be made on cells growing in or deposited on solid surfaces. A common technique is to use a microtiter plate well wherein the fluorescence measurements are made by commercially available fluorescent plate readers. One such method is to use cells in Costar 96 well microtiter plates (flat with a clear bottom) and measure fluorescent signal with CytoFluor multiwell plate reader (Perseptive Biosystems, Inc., MA) using two emission wavelengths to record fluorescent emission ratios. In another embodiment, the system comprises a microvolume liquid handling system that uses electrokinetic forces to control the movement of fluids through channels of the system, for example as described in U.S. patent No., 5,800,690 issued September 1, 1998 to Chow *et al.*, European patent application EP 0 810 438 A2 filed May 5 1997, by Pelc *et al.* and PCT application WO 98/00231 filed 24 June 1997 by Parce *et al.* These systems use "chip" based analysis systems to provide massively parallel miniaturized analysis. Such systems are preferred systems of spectroscopic measurements in some instances that require miniaturized analysis.

A method for identifying a chemical, modulator or a therapeutic

The present invention can also be used for testing a therapeutic for useful therapeutic activity. A therapeutic is identified by contacting a test chemical suspected of having a modulating activity of a biological process or target with a test cell comprising the constructs of the present invention. Typically the cells are located within at least one well of a multi-well platform. The test chemical can be part of a library of test chemicals that is screened for activity, such as biological activity. The library can have individual members that are tested individually or in combination, or the library can be a combination of individual members. Such libraries can have at least two members, preferably greater than about 100 members or greater than about 1,000 members, more preferably greater than about 10,000 members, and most preferably greater than about 100,000 or 1,000,000 members. After appropriate incubation of the sample with the test cell, an inhibitor of protein synthesis may be added and a substrate for the reporter moiety added. At least one optical property (such as fluorescence or absorbance) of the sample is determined and compared to a non-treated control to determine the level of reporter gene expression or activity. If the sample having the test chemical exhibits increased or decreased reporter moiety expression or activity relative to that of the control cell then a candidate modulator has been identified.

The candidate modulator can be further characterized and monitored for structure, potency, toxicology, and pharmacology using well-known methods. The structure of a candidate modulator identified by the invention can be determined or confirmed by methods known in the art, such as mass spectroscopy. For putative modulators stored for extended periods of time, the structure, activity, and potency of the putative modulator can be confirmed.

Depending on the system used to identify a candidate modulator, the candidate modulator will have putative pharmacological activity. For example, if the candidate modulator is found to inhibit a protein tyrosine phosphatase involved, for example in T-cell proliferation *in vitro*, then the candidate modulator would have presumptive pharmacological properties as an immunosuppressant or anti-inflammatory (see, Suthanthiran *et al.*, (1996) Am. J. Kidney Disease, 28 159-172) Such nexuses are known in the art for several disease states, and more are expected to be discovered

over time. Based on such nexuses, appropriate confirmatory *in vitro* and *in vivo* models of pharmacological activity, as well as toxicology, can be selected. The assays, and methods of use described herein, enable rapid pharmacological profiling to assess selectivity and specificity, and toxicity. This data can subsequently be used to develop new candidates with improved characteristics.

Bioavailability and Toxicology of Candidate Modulators

Once identified, candidate modulators can be evaluated for bioavailability and toxicological effects using known methods (see, Lu, Basic Toxicology, Fundamentals, Target Organs, and Risk Assessment, Hemisphere Publishing Corp., Washington (1985); U.S. Patent Nos: 5,196,313 to Culbreth (issued March 23, 1993) and U.S. Patent No. 5,567,952 to Benet (issued October 22, 1996). For example, toxicology of a candidate modulator can be established by determining *in vitro* toxicity towards a cell line, such as a mammalian i.e. human, cell line. Candidate modulators can be treated with, for example, tissue extracts, such as preparations of liver, such as microsomal preparations, to determine increased or decreased toxicological properties of the chemical after being metabolized by a whole organism. The results of these types of studies are often predictive of toxicological properties of chemicals in animals, such as mammals, including humans.

The toxicological activity can be measured using reporter genes that are activated during toxicological activity or by cell lysis (see WO 98/13353, published 4/2/98). Preferred reporter genes produce a fluorescent or luminescent translational product (such as, for example, a Green Fluorescent Protein (see, for example, U.S. Patent No. 5,625,048 to Tsien *et al.*, issued 4/29/98; U.S. Patent No. 5,777,079 to Tsien *et al.*, issued 7/7/98; WO 96/23810 to Tsien, published 8/8/96; WO 97/28261, published 8/7/97; PCT/US97/12410, filed 7/16/97; PCT/US97/14595, filed 8/15/97)) or a translational product that can produce a fluorescent or luminescent product (such as, for example, beta-lactamase (see, for example, U.S. Patent No. 5,741,657 to Tsien, issued 4/21/98, and WO 96/30540, published 10/3/96)), such as an enzymatic degradation product. Cell lysis can be detected in the present invention as a reduction in a fluorescence signal from at least one photon-producing agent within a cell in the presence of at least one photon reducing agent. Such toxicological determinations can

be made using prokaryotic or eukaryotic cells, optionally using toxicological profiling, such as described in PCT/US94/00583, filed 1/21/94 (WO 94/17208), German Patent No 69406772.5-08, issued 11/25/97; EPC 0680517, issued 11/12/94; U.S. Patent No. 5,589,337, issued 12/31/96; EPO 651825, issued 1/14/98; and U.S. Patent No. 5,585,232, issued 12/17/96).

Alternatively, or in addition to these *in vitro* studies, the bioavailability and toxicological properties of a candidate modulator in an animal model, such as mice, rats, rabbits, or monkeys, can be determined using established methods (see, Lu, *supra* (1985); and Creasey, Drug Disposition in Humans, The Basis of Clinical Pharmacology, Oxford University Press, Oxford (1979), Osweiler, *Toxicology*, Williams and Wilkins, Baltimore, MD (1995), Yang, Toxicology of Chemical Mixtures; Case Studies, Mechanisms, and Novel Approaches, Academic Press, Inc., San Diego, CA (1994), Burrell *et al.*, Toxicology of the Immune System; A Human Approach, Van Nostrand Reinhold, Co. (1997), Niesink *et al.*, Toxicology; Principles and Applications, CRC Press, Boca Raton, FL (1996)). Depending on the toxicity, target organ, tissue, locus, and presumptive mechanism of the candidate modulator, the skilled artisan would not be burdened to determine appropriate doses, LD₅₀ values, routes of administration, and regimes that would be appropriate to determine the toxicological properties of the candidate modulator. In addition to animal models, human clinical trials can be performed following established procedures, such as those set forth by the United States Food and Drug Administration (USFDA) or equivalents of other governments. These toxicity studies provide the basis for determining the therapeutic utility of a candidate modulator *in vivo*.

Efficacy of Candidate Modulators

Efficacy of a candidate modulator can be established using several art-recognized methods, such as *in vitro* methods, animal models, or human clinical trials (see, Creasey, *supra* (1979)). Recognized *in vitro* models exist for several diseases or conditions. For example, the ability of a chemical to extend the life-span of HIV-infected cells *in vitro* is recognized as an acceptable model to identify chemicals expected to be efficacious to treat HIV infection or AIDS (see, Daluge *et al.*, (1995) Antimicro. Agents Chemother. 41 1082-1093). Furthermore, the ability of

cyclosporin A (CsA) to prevent proliferation of T-cells *in vitro* has been established as an acceptable model to identify chemicals expected to be efficacious as immunosuppressants (see, Suthanthiran *et al.*, supra, (1996)). For nearly every class of therapeutic, disease, or condition, an acceptable *in vitro* or animal model is available. Such models exist, for example, for gastro-intestinal disorders, cancers, cardiology, neurobiology, and immunology. In addition, these *in vitro* methods can use tissue extracts, such as preparations of liver, such as microsomal preparations, to provide a reliable indication of the effects of metabolism on the candidate modulator. Similarly, acceptable animal models may be used to establish efficacy of chemicals to treat various diseases or conditions. For example, the rabbit knee is an accepted model for testing chemicals for efficacy in treating arthritis (see, Shaw and Lacy, J. (1973) Bone Joint Surg. (Br) 55 197-205. Hydrocortisone, which is approved for use in humans to treat arthritis, is efficacious in this model which confirms the validity of this model (see, McDonough, (1982) Phys. Ther. 62 835-839). When choosing an appropriate model to determine efficacy of a candidate modulator, the skilled artisan can be guided by the state of the art to choose an appropriate model, dose, and route of administration, regime, and endpoint and as such would not be unduly burdened.

In addition to animal models, human clinical trials can be used to determine the efficacy of a candidate modulator in humans. The USFDA, or equivalent governmental agencies, have established procedures for such studies (see, www.fda.gov).

Selectivity of Candidate Modulators

The *in vitro* and *in vivo* methods described above also establish the selectivity of a candidate modulator. It is recognized that chemicals can modulate a wide variety of biological processes or be selective. Panels of cells, each containing constructs with varying specificity, based on the red fluorescent proteins of the present invention, can be used to determine the specificity of the candidate modulator. Selective modulators are preferable because they have fewer side effects in the clinical setting. The selectivity of a candidate modulator can be established *in vitro* by testing the toxicity and effect of a candidate modulator on a plurality of cell lines that exhibit a variety of cellular pathways and sensitivities. The data obtained from

these *in vitro* toxicity studies can be extended into *in vivo* animal model studies, including human clinical trials, to determine toxicity, efficacy, and selectivity of the candidate modulator using art-recognized methods.

5 *An identified chemical, modulator, or therapeutic and compositions*

The invention includes compositions, such as novel chemicals, and therapeutics identified by at least one method of the present invention as having activity by the operation of methods, systems or components described herein. Novel chemicals, as used herein, do not include chemicals already publicly known in the art
10 as of the filing date of this application. Typically, a chemical would be identified as having activity from using the invention and then its structure can be revealed from a proprietary database of chemical structures or determined using analytical techniques such as mass spectroscopy.

One embodiment of the invention is a chemical with useful activity,
15 comprising a chemical identified by the method described above. Such compositions include small organic molecules, nucleic acids, peptides and other molecules readily synthesized by techniques available in the art and developed in the future. For example, the following combinatorial compounds are suitable for screening: peptoids (PCT Publication No. WO 91/19735, 26 Dec. 1991), encoded peptides (PCT
20 Publication No. WO 93/20242, 14 Oct. 1993), random bio-oligomers (PCT Publication WO 92/00091, 9 Jan. 1992), benzodiazepines (U.S. Patent No. 5,288,514), diversomeres such as hydantoins, benzodiazepines and dipeptides (Hobbs DeWitt, S. *et al.*, (1993) Proc. Nat. Acad. Sci. USA 90 6909-6913), vinylogous polypeptides (Hagihara *et al.*, (1992) J. Amer. Chem. Soc. 114 6568), nonpeptidal
25 peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann, R. *et al.*, (1992) J. Amer. Chem. Soc. 114 9217-9218), analogous organic syntheses of small compound libraries (Chen, C. *et al.*, (1994) J. Amer. Chem. Soc. 116 2661), oligocarbamates (Cho, C.Y. *et al.*, (1993) Science 261: 1303), and/or peptidyl phosphonates (Campbell, D.A. *et al.*, (1994) J. Org. Chem. 59 658). See, generally, Gordon, E. M.
30 *et al.*, (1994). J. Med Chem. 37 1385. The contents of all of the aforementioned publications are incorporated herein by reference.

The present invention also encompasses the identified compositions in a pharmaceutical composition comprising a pharmaceutically acceptable carrier prepared for storage and subsequent administration, which have a pharmaceutically effective amount of the products disclosed above in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985). Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition. For example, sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives. In addition, antioxidants and suspending agents may be used.

The compositions of the present invention may be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; sterile solutions, suspensions for injectable administration; and the like. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like. In addition, if desired, the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like. If desired, absorption enhancing preparations (e.g., liposomes) may be utilized.

The pharmaceutically effective amount of the composition required as a dose will depend on the route of administration, the type of animal being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. In practicing the methods of the invention, the products or compositions can be used alone or in combination with one another or in combination with other therapeutic or diagnostic agents. These products can be utilized *in vivo*, ordinarily in a mammal, preferably in a human, or *in vitro*. In employing them *in vivo*, the products or compositions can be administered to the mammal in a variety of ways,

including parenterally, intravenously, subcutaneously, intramuscularly, colonically, rectally, nasally or intraperitoneally, employing a variety of dosage forms. Such methods may also be applied to testing chemical activity *in vivo*.

As will be readily apparent to one skilled in the art, the useful *in vivo* dosage to be administered and the particular mode of administration will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed. The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable *in vitro* studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.

In non-human animal studies, applications of potential products are commenced at higher dosage levels, with dosage being decreased until the desired effect is no longer achieved or adverse side effects disappear. The dosage for the products of the present invention can range broadly depending upon the desired affects and the therapeutic indication. Typically, dosages may be between about 10 mg/kg and 100 mg/kg body weight, and preferably between about 100 µg/kg and 10 mg/kg body weight. Administration is preferably oral on a daily basis.

The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl *et al.*, in The Pharmacological Basis of Therapeutics, 1975). It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administered dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body

weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.

Depending on the specific conditions being treated, such agents may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990). Suitable routes may include oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, then administered as described above. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external micro-environment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to

their hydrophobicity, small organic molecules may be directly administered intracellularly.

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to
5 achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into
10 preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions. The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, for example, by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating,
15 entrapping, or lyophilizing processes.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or
20 synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated
25 solutions.

Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as
30 sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium

carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. Such formulations can be made using methods known in the art (see, for example, U.S. Patent Nos. 5,733,888 (injectable compositions); 5,726,181 (poorly water soluble compounds); 5,707,641 (therapeutically active proteins or peptides); 5,667,809 (lipophilic agents); 5,576,012 (solubilizing polymeric agents); 5,707,615 (anti-viral formulations); 5,683,676 (particulate medicaments); 5,654,286 (topical formulations); 5,688,529 (oral suspensions); 5,445,829 (extended release formulations); 5,653,987 (liquid formulations); 5,641,515 (controlled release formulations) and 5,601,845 (spheroid formulations)).

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

<110> VERTEX PHARMACEUTICALS (SAN DIEGO) LLC

<120> MODIFIED FLUORESCENT PROTEINS

<130> 581-267

<140> N/A

<150> US 60/184,732

<151> 2000-02-23

<160> 51

<170> PatentIn version 3.0

<210> 1

<211> 690

<212> DNA

<213> Anemonia majano

<400> 1

```

atggctcttt caaacaagtt tatcggagat gacatgaaaa tgacctacca tatggatggc      60
tgtgtcaatg ggcattactt taccgtcaaa ggtgaaggca acgggaagcc atacgaaggg      120
acgcagactt cgacttttaa agtcaccatg gccaacggtg ggccccttgc attctccttt      180
gacatactat ctacagtgtt caaatatgga aatcgatgct ttactgcgta tcctaccagt      240
atgcccgact atttcaaaca agcatttcct gacggaatgt catatgaaag gacttttacc      300
tatgaagatg gaggagttgc tacagccagt tgggaaataa gccttaaagg caactgcttt      360
gagcacaaat ccacgtttca tggagtgaac tttcctgctg atggacctgt gatggcgaag      420
aagacaactg gttgggaccc atcttttgag aaaatgactg tctgcgatgg aatattgaag      480
ggtgatgtca ccgcgttcct catgctgcaa ggaggtggca attacagatg ccaattccac      540
acttcttaca agacaaaaaa accggtgacg atgccaccaa accatgtggg ggaacatcgc      600
attgcgagga ccgaccttga caaaggtggc aacagtgttc agctgacgga gcacgctgtt      660
gcacatataa cctctgttgt ccctttctga                                     690

```

<210> 2

<211> 696

<212> DNA

<213> Zoanthus sp

<400> 2

```

atggctcagt caaagcacgg tctaacaaaa gaaatgacaa tgaaataccg tatggaaggg      60
tgcgtcgatg gacataaatt tgtgatcacg ggagaggggca ttggatatcc gttcaaaggg      120

```

aaacaggcta ttaatctgtg tgtggtcgaa ggtggaccat tgccatttgc cgaagacata 180
 ttgtcagctg cctttaacta cggaaacagg gttttcactg aatatacctca agacatagtt 240
 gactatttca agaactcgtg tcctgctgga tatacatggg acaggtcttt tctctttgag 300
 gatggagcag tttgcatatg taatgcagat ataacagtga gtgttgaaga aaactgcatg 360
 tatcatgagt ccaaatttta tggagtgaat tttcctgctg atggacctgt gatgaaaaag 420
 atgacagata actgggagcc atcctgcgag aagatcatac cagtaccta gcaggggata 480
 ttgaaagggg atgtctccat gtacctcctt ctgaaggatg gtgggcgttt acggtgccaa 540
 ttcgacacag ttacaaagc aaagtctgtg ccaagaaaga tgccggactg gcacttcac 600
 cagcataagc tcacccgtga agaccgcagc gatgctaaga atcagaaatg gcacttgaca 660
 gaacatgcta ttgcatccgg atctgcattg ccctga 696

<210> 3
 <211> 696
 <212> DNA
 <213> Zoanthus sp

<400> 3
 atggctcatt caaagcacgg tctaaaagaa gaaatgacaa tgaaatacca catggaaggg 60
 tgcgtcaacg gacataaatt tgtgatcacg ggcgaaggca ttggatatcc gttcaaaggg 120
 aaacagacta ttaatctgtg tgtgatcgaa gggggaccat tgccattttc cgaagacata 180
 ttgtcagctg gctttaagta cggagacagg attttcactg aatatacctca agacatagta 240
 gactatttca agaactcgtg tcctgctgga tatacatggg gcaggtcttt tctctttgag 300
 gatggagcag tctgcatatg caatgtagat ataacagtga gtgtcaaaga aaactgcatt 360
 tatcataaga gcatatttaa tggaatgaat tttcctgctg atggacctgt gatgaaaaag 420
 atgacaacta actgggaagc atcctgcgag aagatcatgc cagtaccta gcaggggata 480
 ctgaaagggg atgtctccat gtacctcctt ctgaaggatg gtgggcgtta ccggtgccag 540
 ttcgacacag ttacaaagc aaagtctgtg ccaagtaaga tgccggagtg gcacttcac 600
 cagcataagc tcctccgtga agaccgcagc gatgctaaga atcagaagtg gcagctgaca 660
 gagcatgcta ttgcattccc ttctgccttg gcctga 696

<210> 4
 <211> 699
 <212> DNA
 <213> Discosoma striata

<400> 4

```

atgagttggt ccaagagtgt gatcaaggaa gaaatgttga tcgatcttca tctggaagga      60
acgttcaatg ggcactactt tgaaataaaa ggcaaaggaa aaggacagcc taatgaaggc      120
accaataaccg tcacgctcga ggttaccaag ggtggacctc tgccatttgg ttggcatatt      180
ttgtgcccac aatttcagta tggaaacaag gcatttgtcc accaccctga caacatacat      240
gattatctaa agctgtcatt tccggaggga tatacatggg aacgggccat gcactttgaa      300
gacggtggct tgtgttgtat caccaatgat atcagtttga caggcaactg tttctactac      360
gacatcaagt tcaactggctt gaactttcct ccaaattggac ccgttgtgca gaagaagaca      420
actggctggg aaccgagcac tgagcgtttg taccctcgtg atggtgtggt gataggagac      480
atccatcatg ctctgacagt tgaaggaggt ggtcattacg catgtgacat taaaactggt      540
tacagggcca agaaggccgc cttgaagatg ccagggtatc actatgttga caccaaactg      600
gttatatgga acaacgacaa agaattcatg aaagttgagg agcatgaaat cgccgttgca      660
cgccaccatc cgttctatga gccaaagaag gataagtaa                                699

```

<210> 5

<211> 678

<212> DNA

<213> Discosoma sp "red"

<400> 5

```

atgaggtctt ccaagaatgt tatcaaggag ttcatgaggt ttaaggttcg catggaagga      60
acggtcaatg ggcacgagtt tgaaatagaa ggccaaggag aggggaggcc atacgaaggc      120
cacaataaccg taaagcttaa ggtaaccaag gggggacctt tgccatttgc ttgggatatt      180
ttgtcaccac aatttcagta tggaagcaag gtatatgtca agcaccctgc cgacatacca      240
gactataaaa agctgtcatt tcctgaagga tttaaattgg aaagggtcat gaactttgaa      300
gacggtggcg tcgttactgt aaccaggat tccagtttgc aggatggctg tttcatctac      360
aaggtcaagt tcattggcgt gaactttcct tccgatggac ctgttatgca aaagaagaca      420
atgggctggg aagccagcac tgagcgtttg taccctcgtg atggcgtggt gaaaggagag      480
attcataagg ctctgaagct gaaagacggt ggtcattacc tagttgaatt caaaagtatt      540
tacatggcaa agaagcctgt gcagctacca gggactact atgttgactc caaactggat      600
ataacaagcc acaacgaaga ctatacaatc gttgagcagt atgaaagaac cgagggacgc      660
caccatctgt tcctttaa                                678

```

<210> 6
 <211> 801
 <212> DNA
 <213> Clavularia sp

<400> 6
 atgaagtgtgta aatttgtgtt ctgcctgtcc ttcttgggtcc tcgccatcac aaacgcgaac 60
 atttttttga gaaacgagggc tgacttagaa gagaagacat tgagaatacc aaaagctcta 120
 accaccatgg gtgtgattaa accagacatg aagattaagc tgaagatgga aggaaatgta 180
 aacgggcatg cttttgtgat cgaaggagaa ggagaaggaa agccttacga tgggacacac 240
 actttaaaccc tgggaagtga ggaagggtgcg cctctgcctt tttcttacga tatcttgtca 300
 aacgcgttcc agtacggaaa cagagcattg acaaaatacc cagacgatat agcagactat 360
 ttcaagcagt cgtttcccga gggatattcc tgggaaagaa ccatgacttt tgaagacaaa 420
 ggcattgtca aagtgaaaag tgacataagc atggaggaag actcctttat ctatgaaatt 480
 cgttttgatg ggatgaactt tcctcccaat ggtccgggta tgcagaaaaa aactttgaag 540
 tgggaaccat ccactgagat tatgtacgtg cgtgatggag tgctggtcgg agatattagc 600
 cattctctgt tgctggaggg aggtggccat taccgatgtg acttcaaaag tatttacaaa 660
 gcaaaaaaag ttgtcaaatt gccagactat cactttgtgg accatcgcat tgagatcttg 720
 aaccatgaca aggattacaa caaagtaacg ctgtatgaga atgcagttgc tcgctattct 780
 ttgctgccaa gtcaggccta g 801

<210> 7
 <211> 225
 <212> PRT
 <213> Anthozoan red fluorescent protein

<400> 7
 Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val
 1 5 10 15
 Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
 20 25 30
 Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys Val
 35 40 45
 Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln
 50 55 60
 Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro
 65 70 75 80

Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val
 85 90 95
 Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
 100 105 110
 Leu Gln Asp Gly Cys Phe Ile Tyr Lys Val Lys Phe Ile Gly Val Asn
 115 120 125
 Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu
 130 135 140
 Ala Ser Thr Glu Arg Leu Tyr Pro Arg Asp Gly Val Leu Lys Gly Glu
 145 150 155 160
 Ile His Lys Ala Leu Lys Leu Lys Asp Gly Gly His Tyr Leu Val Glu
 165 170 175
 Phe Lys Ser Ile Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr
 180 185 190
 Tyr Tyr Val Asp Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr
 195 200 205
 Thr Ile Val Glu Gln Tyr Glu Arg Thr Glu Gly Arg His His Leu Phe
 210 215 220

Leu
 225

<210> 8
 <211> 681
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Mutant Anthozoan red fluorescent protein

<220>
 <221> CDS
 <222> (1)..(681)

<400> 8
 atg gtg agg agc agc aag aac gtg atc aag gag ttc atg agg ttc aag 48
 Met Val Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys
 1 5 10 15
 gtg cgc atg gag ggc acc gtg aac ggc cac gag ttc gag atc gag ggc 96
 Val Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly
 20 25 30
 gag ggc gag ggc agg ccc tac gag ggc cac aac acc gtg aag ctt aag 144
 Glu Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys
 35 40 45
 gtg acc aag ggc ggc ccc ctg ccc ttc gcc tgg gac atc ctg agc ccc 192

Val	Thr	Lys	Gly	Gly	Pro	Leu	Pro	Phe	Ala	Trp	Asp	Ile	Leu	Ser	Pro		
50						55					60						
cag	ttc	cag	tac	ggc	agc	aag	gtg	tac	gtg	aag	cac	ccc	gcc	gac	atc		240
Gln	Phe	Gln	Tyr	Gly	Ser	Lys	Val	Tyr	Val	Lys	His	Pro	Ala	Asp	Ile		
65					70					75					80		
ccc	gac	tac	aag	aag	ctg	agc	ttc	ccc	gag	ggc	ttc	aag	tgg	gag	agg		288
Pro	Asp	Tyr	Lys	Lys	Leu	Ser	Phe	Pro	Glu	Gly	Phe	Lys	Trp	Glu	Arg		
				85					90					95			
gtg	atg	aac	ttc	gag	gac	ggc	ggc	gtg	gtg	acc	gtg	acc	cag	gac	agc		336
Val	Met	Asn	Phe	Glu	Asp	Gly	Gly	Val	Val	Thr	Val	Thr	Gln	Asp	Ser		
			100					105					110				
agc	ctg	cag	gac	ggc	tgc	ttc	atc	tac	aag	gtg	aag	ttc	atc	ggc	gtg		384
Ser	Leu	Gln	Asp	Gly	Cys	Phe	Ile	Tyr	Lys	Val	Lys	Phe	Ile	Gly	Val		
		115					120					125					
aac	ttc	ccc	agc	gac	ggc	ccc	gtg	atg	cag	aag	aag	acc	atg	ggc	tgg		432
Asn	Phe	Pro	Ser	Asp	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Met	Gly	Trp		
	130					135						140					
gag	gcc	tcc	acc	gag	cgc	ctg	tac	ccc	cgc	gac	ggc	gtg	ctg	aag	ggc		480
Glu	Ala	Ser	Thr	Glu	Arg	Leu	Tyr	Pro	Arg	Asp	Gly	Val	Leu	Lys	Gly		
145					150					155					160		
gag	atc	cac	aag	gcc	ctg	aag	ctg	aag	gac	ggc	ggc	cac	tac	ctg	gtg		528
Glu	Ile	His	Lys	Ala	Leu	Lys	Leu	Lys	Asp	Gly	Gly	His	Tyr	Leu	Val		
				165					170					175			
gag	ttc	aag	tcc	atc	tac	atg	gcc	aag	aag	ccc	gtg	cag	ctg	ccc	ggc		576
Glu	Phe	Lys	Ser	Ile	Tyr	Met	Ala	Lys	Lys	Pro	Val	Gln	Leu	Pro	Gly		
			180					185					190				
tac	tac	tac	gtg	gac	tcc	aag	ctg	gac	atc	acc	agc	cac	aac	gag	gac		624
Tyr	Tyr	Tyr	Val	Asp	Ser	Lys	Leu	Asp	Ile	Thr	Ser	His	Asn	Glu	Asp		
			195				200					205					
tac	acc	atc	gtg	gag	cag	tac	gag	agg	acc	gag	ggc	agg	cac	cac	ctg		672
Tyr	Thr	Ile	Val	Glu	Gln	Tyr	Glu	Arg	Thr	Glu	Gly	Arg	His	His	Leu		
	210					215					220						
ttc	ctg	tga															681
Phe	Leu																
225																	

<210> 9
 <211> 226
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Mutant Anthozoan red fluorescent protein

<400> 9

Met 1	Val	Arg	Ser	Ser 5	Lys	Asn	Val	Ile	Lys 10	Glu	Phe	Met	Arg	Phe 15	Lys
Val	Arg	Met	Glu 20	Gly	Thr	Val	Asn	Gly 25	His	Glu	Phe	Glu	Ile 30	Glu	Gly
Glu	Gly	Glu 35	Gly	Arg	Pro	Tyr	Glu 40	Gly	His	Asn	Thr	Val 45	Lys	Leu	Lys
Val 50	Thr	Lys	Gly	Gly	Pro	Leu 55	Pro	Phe	Ala	Trp	Asp 60	Ile	Leu	Ser	Pro
Gln 65	Phe	Gln	Tyr	Gly	Ser 70	Lys	Val	Tyr	Val	Lys 75	His	Pro	Ala	Asp	Ile 80
Pro	Asp	Tyr	Lys	Lys 85	Leu	Ser	Phe	Pro	Glu 90	Gly	Phe	Lys	Trp	Glu 95	Arg
Val	Met	Asn	Phe 100	Glu	Asp	Gly	Gly	Val 105	Val	Thr	Val	Thr	Gln 110	Asp	Ser
Ser	Leu	Gln 115	Asp	Gly	Cys	Phe	Ile 120	Tyr	Lys	Val	Lys	Phe 125	Ile	Gly	Val
Asn	Phe 130	Pro	Ser	Asp	Gly	Pro 135	Val	Met	Gln	Lys	Lys 140	Thr	Met	Gly	Trp
Glu 145	Ala	Ser	Thr	Glu	Arg 150	Leu	Tyr	Pro	Arg	Asp 155	Gly	Val	Leu	Lys	Gly 160
Glu	Ile	His	Lys	Ala 165	Leu	Lys	Leu	Lys	Asp 170	Gly	Gly	His	Tyr	Leu 175	Val
Glu	Phe	Lys	Ser 180	Ile	Tyr	Met	Ala	Lys 185	Lys	Pro	Val	Gln	Leu 190	Pro	Gly
Tyr	Tyr	Tyr 195	Val	Asp	Ser	Lys	Leu 200	Asp	Ile	Thr	Ser	His 205	Asn	Glu	Asp
Tyr	Thr 210	Ile	Val	Glu	Gln	Tyr 215	Glu	Arg	Thr	Glu	Gly 220	Arg	His	His	Leu

Phe Leu
225

<210> 10
<211> 720
<212> DNA
<213> Aequorea victoria

<400> 10
atggtgagca agggcgagga gctgttcacc ggggtggtgc ccatcctggt cgagctggac 60
ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg gcgagggcga tgccacctac 120
ggcaagctga ccctgaagtt catctgcacc accggcaagc tgcccgtgcc ctggcccacc 180
ctcgtgacca ctttctccta cggcgtgcag tgcttcagcc gctaccccga ccacatgaag 240
cagcagcact tcttcaagtc cgccatgccc gaaggctacg tccaggagcg caccatcttc 300
ttcaaggacg acggcaacta caagacccgc gccgaggtga agttcgaggg cgacaccctg 360
gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg acggcaacat cctggggcac 420
aacctggagt acaactacaa cagccacaac gtctatatca tggccgacaa gcagaagaac 480
ggcatcaagg tgaacttcaa gatccgccac aacatcgagg acggcagcgt gcagctcgcc 540
gaccactacc agcagaacac ccccatcggc gacggccccg tgctgctgcc cgacaaccac 600
tacctgagca ccagtcgcgc cctgagcaaa gacccaacg agaagcgcgga tcacatggtc 660
ctgctggagt tcgtgaccgc cgccgggata actctcggca tggacgagct gtacaagtaa 720

<210> 11
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 58

<400> 11

Asp Ala His Pro
1

<210> 12
<211> 12
<212> DNA
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 58

<400> 12
gacgcgcacc cc

12

<210> 13
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 63

<400> 13

Gln Lys Pro Thr
1

<210> 14
<211> 12
<212> DNA
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 63

<400> 14
cagaagcgga cg

12

<210> 15
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
No. 9) at relative position GFP 64

<400> 15

Phe Val Ile Leu
1

<210> 16
<211> 12
<212> DNA
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
No. 9) at relative position GFP 64

<400> 16
ttcgtsatct tg

12

<210> 17
 <211> 8
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
 NO. 9) at relative position GFP 65

<400> 17

Gln Arg Pro Lys Glu Thr Ala Gly
 1 5

<210> 18
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
 NO. 9) at relative position GFP 65

<400> 18
 cagmgscgga aggagacggc gggg

24

<210> 19
 <211> 4
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
 NO. 9) at relative position GFP 68

<400> 19

Ser Leu Ala Val
 1

<210> 20
 <211> 12
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
 NO. 9) at relative position GFP 68

<400> 20
 tcgttggcgg tg

12

<210> 21

<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 69

<400> 21

Lys Met Gln Leu
1

<210> 22
<211> 12
<212> DNA
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 69

<400> 22
aagatgcagc tg

12

<210> 23
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 72

<400> 23

Val Ala Leu Ser
1

<210> 24
<211> 12
<212> DNA
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 72

<400> 24
gtggcggttg cg

12

<210> 25
<211> 4
<212> PRT
<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 94

<400> 25

Trp Leu Cys Phe
1

<210> 26

<211> 12

<212> DNA

<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 94

<400> 26

tggttgctgc tc

12

<210> 27

<211> 4

<212> PRT

<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 99

<400> 27

Asn Thr Asp Ala
1

<210> 28

<211> 12

<212> DNA

<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 99

<400> 28

aacaccgacg cc

12

<210> 29

<211> 4

<212> PRT

<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.

NO. 9) at relative position GFP 145

<400> 29

Trp Leu Cys Phe
1

<210> 30

<211> 12

<212> DNA

<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 145

<400> 30

tggttgctgc tc

12

<210> 31

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 148

<400> 31

Ser Arg Gly Asn His Asp
1 5

<210> 32

<211> 18

<212> DNA

<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 148

<400> 32

agccgcggca accacgac

18

<210> 33

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 153

<400> 33

Tyr Asn Asp Ser Thr Ala
1 5

<210> 34
<211> 18
<212> DNA
<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID. NO. 9) at relative position GFP 153

<400> 34
tacaacgact ccaccgcc

18

<210> 35
<211> 5
<212> PRT
<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID. NO. 9) at relative position GFP 165

<400> 35

Ile Val Phe Met Leu
1 5

<210> 36
<211> 15
<212> DNA
<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID. NO. 9) at relative position GFP 165

<400> 36
atcgtsttca tgttg

15

<210> 37
<211> 8
<212> PRT
<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID. NO. 9) at relative position GFP 167

<400> 37

Lys Ile Arg Thr Glu Val Gly Ala
1 5

<210> 38
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID. NO. 9) at relative position GFP 168

<400> 38

aaaataagaa cagaagtagg agca

24

<210> 39
 <211> 8
 <212> PRT
 <213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID. NO. 9) at relative position GFP 183

<220>

<221> VARIANT

<222> (5)..(5)

<223> Xaa is termination site

<400> 39

Ser Ala Pro Thr Xaa Glu Gln Lys

1

5

<210> 40
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID. NO. 9) at relative position GFP 183

<400> 40

tcagcaccaa cataagaaca aaaa

24

<210> 41
 <211> 4
 <212> PRT
 <213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID. NO. 9) at relative position GFP 185

<400> 41

Tyr Phe Asn Ile

1

<210> 42
<211> 12
<212> DNA
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 185

<400> 42
tacttcaaca tc 12

<210> 43
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 203

<400> 43

Ser Tyr Thr Asn

1

<210> 44
<211> 12
<212> DNA
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 203

<400> 44
tcctacacca ac 12

<210> 45
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 221

<400> 45

Tyr Phe His Leu

1

<210> 46
<211> 12
<212> DNA
<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 221

<400> 46
tacttccacc tc

12

<210> 47
<211> 4
<212> PRT
<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 222

<400> 47

Glu Gly Gln Arg
1

<210> 48
<211> 12
<212> DNA
<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 222

<400> 48
gaggggcagc gg

12

<210> 49
<211> 4
<212> PRT
<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID.
NO. 9) at relative position GFP 223

<400> 49

Arg Leu Cys Phe
1

<210> 50
<211> 12
<212> DNA

<213> Artificial sequence

<220>

<223> Mutagenic sequence for insertion into synthetic gene (SEQ. ID. NO. 9) at relative position GFP 223

<400> 50

cgctctgct tc

12

<210> 51

<211> 713

<212> DNA

<213> Artificial sequence

<220>

<223> Mutant Anthozoan red fluorescent protein

<400> 51

ccgaattctc gagccaccat ggtgaggagc agcaagaacg tgatcaagga gttcatgagg 60

ttcaagggtgc gcatggaggg caccgtgaac ggccacgagt tcgagatcga gggcgagggc 120

gagggcaggc cctacgaggg ccacaacacc gtgaagctta aggtgaccaa gggcggcccc 180

ctgcccttcg cctgggacat cctgagcccc cagttccagt acggcagcaa ggtgtacgtg 240

aagcaccctc cgcacatccc cgactacaag aagctgagct tccccgaggg cttcaagtgg 300

gagaggggtga tgaacttcga ggacggcggc gtggtgaccg tgaccagga cagcagcctg 360

caggacggct gcttcatcta caaggtgaag ttcacggcg tgaacttccc cagcgacggc 420

cccgtgatgc agaagaagac catgggctgg gaggcctcca ccgagcgct gtacccccgc 480

gacggcgtgc tgaagggcga gatccacaag gccctgaagc tgaaggacgg cggccactac 540

ctggtggagt tcaagtccat ctacatggcc aagaagcccg tgcagctgcc cggctactac 600

tacgtggact ccaagctgga catcaccagc cacaacgagg actacaccat cgtggagcag 660

tacgagagga ccgagggcag gcaccacctg ttcctgtgag tcgacgttaa ccc 713

58

WHAT IS CLAIMED IS:

1. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
2. The nucleic acid molecule of claim 1, wherein said functional red fluorescent protein exhibits a reduced molar extinction coefficient at 487 nm compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
3. The nucleic acid molecule of claim 1, wherein said functional red fluorescent protein exhibits a reduced molar extinction coefficient at 530 nm compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
4. The nucleic acid molecule of claim 1, wherein said functional red fluorescent protein exhibits a higher molar extinction coefficient at 583 nm compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
5. The nucleic acid molecule of claim 1, wherein said functional red fluorescent protein is brighter than said Anthozoan red fluorescent protein (SEQ. ID. NO. 7) when excited at 558 nm.
6. The nucleic acid molecule of claim 1, wherein said functional red fluorescent protein is brighter than said Anthozoan red fluorescent protein (SEQ. ID. NO. 7) when expressed in a mammalian cell grown at 37 °C.

7. The nucleic acid molecule of claim 1, wherein said functional red fluorescent protein exhibits a higher quantum yield compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
- 5 8. The nucleic acid molecule of claim 1, wherein said functional red fluorescent protein exhibits a faster rate of autocatalytic formation compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
9. A nucleic acid molecule, comprising; a nucleotide sequence encoding a
10 functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 59, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
- 15 10. The nucleic acid molecule of claim 9, wherein said at least one amino acid substitution at position 59 is selected from the group consisting of D59S, D59A, D59H, D59E and D59P.
- 20 11. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 60, wherein said functional red
25 fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
12. The nucleic acid molecule of claim 11, wherein said at least one amino acid substitution at position 60 is selected from the group consisting of I60T, I60A,
30 I60C, I60V and I60L.

13. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 62, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
14. The nucleic acid molecule of claim 13, wherein said at least one amino acid substitution at position 62 is selected from the group consisting of S62A, S62G, S62C and S62T.
15. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 63, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
16. The nucleic acid molecule of claim 15, wherein said at least one amino acid substitution at position 63 is selected from the group consisting of P63T, P63H, P63F and P63W.
17. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 64, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
18. The nucleic acid molecule of claim 17, wherein said at least one amino acid substitution at position 64 is selected from the group consisting of Q64K, Q64P, Q64T, Q64N and Q64R.

19. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 65, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
20. The nucleic acid molecule of claim 19, wherein said at least one amino acid substitution at position 65 is selected from the group consisting of F65L, F65V, F65I, F65M, F65Y and F65W.
21. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 66, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
22. The nucleic acid molecule of claim 21, wherein said at least one amino acid substitution at position 66 is selected from the group consisting of Q66R, Q66P, Q66K, Q66E, Q66T, Q66A and Q66G.
23. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 69, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
24. The nucleic acid molecule of claim 23, wherein said at least one amino acid substitution at position 69 is selected from the group consisting of S69L, S69A, S69V and S69T.

25. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 70, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
26. The nucleic acid molecule of claim 25, wherein said at least one amino acid substitution at position 70 is selected from the group consisting of K70M, K70Q, K70L and K70R.
27. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 71, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
28. The nucleic acid molecule of claim 27, wherein said at least one amino acid substitution at position 71 is selected from the group consisting of V71C, V71L, V71A and V71I.
29. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 72, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
30. The nucleic acid molecule of claim 29, wherein said at least one amino acid substitution at position 72 is selected from the group consisting of Y72F and Y72W.

31. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 73, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
32. The nucleic acid molecule of claim 31, wherein said at least one amino acid substitution at position 73 is selected from the group consisting of V73A, V73L, V73S and V73I.
33. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 93, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
34. The nucleic acid molecule of claim 33, wherein said at least one amino acid substitution at position 93 is selected from the group consisting of W93L, W93Y, W93C and W93F.
35. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 95, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
36. The nucleic acid molecule of claim 35, wherein said at least one amino acid substitution at position 95 is selected from the group consisting of R95K.

37. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 98, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
38. The nucleic acid molecule of claim 37, wherein said at least one amino acid substitution at position 98 is selected from the group consisting of N98T, N98D, N98A and N98Q.
39. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 143, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
40. The nucleic acid molecule of claim 39, wherein said at least one amino acid substitution at position 143 is selected from the group consisting of W143L, W143F, W143C, W143Y and W143L.
41. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 145, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
42. The nucleic acid molecule of claim 41, wherein said at least one amino acid substitution at position 145 is selected from the group consisting of A145P, A145S, A145G and A145L.

43. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 146, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
44. The nucleic acid molecule of claim 43, wherein said at least one amino acid substitution at position 146 is selected from the group consisting of S146R, S146G, S146N, S146H, S146T, S146A and S146D
45. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 147, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
46. The nucleic acid molecule of claim 45, wherein said at least one amino acid substitution at position 147 is selected from the group consisting of T147N, T147K and T147S.
47. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 148, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
48. The nucleic acid molecule of claim 46, wherein said at least one amino acid substitution at position 148 is selected from the group consisting of E148V and E148D.

49. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 151, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
50. The nucleic acid molecule of claim 49, wherein said at least one amino acid substitution at position 151 is selected from the group consisting of Y151F, Y151N, Y151D, Y151S, Y151T and Y151A.
51. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 159, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
52. The nucleic acid molecule of claim 51, wherein said at least one amino acid substitution at position 159 is selected from the group consisting of G159A, G159S and G159V.
53. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 161, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
54. The nucleic acid molecule of claim 53, wherein said at least one amino acid substitution at position 161 is selected from the group consisting of I161V, I161V, I161F, I161M and I161L

55. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 163, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
56. The nucleic acid molecule of claim 55, wherein said at least one amino acid substitution at position 163 is selected from the group consisting of K163I, K163R, K163T, K163E, K163V, K163G and K163A.
57. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 171, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
58. The nucleic acid molecule of claim 57, wherein said at least one amino acid substitution at position 171 is selected from the group consisting of G171S and G171A.
59. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 179, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
60. The nucleic acid molecule of claim 59, wherein said at least one amino acid substitution at position 179 is selected from the group consisting of S179A, S179P, S179T, S179E, S179Q and S179K.

61. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 181, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
62. The nucleic acid molecule of claim 61, wherein said at least one amino acid substitution at position 181 is selected from the group consisting of Y181F, Y181W, Y181N and Y181I.
63. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 197, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
64. The nucleic acid molecule of claim 63, wherein said at least one amino acid substitution at position 197 is selected from the group consisting of S197Y, S197T, S197N and S197A.
65. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 199, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
66. The nucleic acid molecule of claim 65, wherein said at least one amino acid substitution at position 199 is selected from the group consisting of L199I, L199V, L199I and L199A.

67. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 214, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
68. The nucleic acid molecule of claim 67, wherein said at least one amino acid substitution at position 214 is selected from the group consisting of Y214F, Y214H and Y214L.
69. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 215, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
70. The nucleic acid molecule of claim 69, wherein said at least one amino acid substitution at position 215 is selected from the group consisting of E215G, E215Q and E215R.
71. A nucleic acid molecule, comprising; a nucleotide sequence encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position 216, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
72. The nucleic acid molecule of claim 71, wherein said at least one amino acid substitution at position 216 is selected from the group consisting of R216K, R216L, R216C and R216F.

73. An expression vector, comprising; expression control sequences operatively linked to a nucleic acid molecule encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
74. A recombinant host cell, comprising; a nucleic acid molecule encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
75. A functional fluorescent protein, comprising; an amino acid sequence that differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).

76. A fusion protein, comprising; a protein of interest operably coupled to a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position D59, I60, S62, P63, Q64, F65, Q66,
5 S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
- 10 77. A transgenic organism, comprising; a nucleic acid molecule encoding a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position D59, I60, S62, P63, Q64, F65, Q66,
15 S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7).
- 20 78. A method for identifying a protein – protein interaction, comprising;
a) providing a population of cells comprising,
a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ.
25 ID. NO. 7) by at least one amino acid substitution at position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179, Y181, S197, L199, Y214, E215 or R216, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7),
30 and wherein said functional red fluorescent protein is operably coupled to a first protein of interest,

- 5 b) introducing a library of test proteins of interest operably coupled to a functional green fluorescent protein into said population of cells, wherein said functional green fluorescent protein and said functional red fluorescent protein can undergo fluorescence energy transfer (FRET), and
- wherein each member of said population of cells receives on average one member of said library of test proteins of interest operably coupled to said functional green fluorescent protein,
- 10 c) screening said population of cells for FRET between said functional green fluorescent protein and said functional red fluorescent protein, and
- d) comparing the FRET in step c) to the FRET in a control cell in the absence of said library of test proteins of interest operably coupled to said functional green fluorescent protein.
- 15
79. A method for identifying a modulator of protein – protein interactions, comprising;
- a) contacting a cell with a test chemical, wherein said cell comprises,
- 20 i) a functional red fluorescent protein whose sequence differs from the amino acid sequence of an Anthozoan red fluorescent protein (SEQ. ID. NO. 7) by at least one amino acid substitution at position D59, I60, S62, P63, Q64, F65, Q66, S69, K70, V71, Y72, V73, W93, R95, N98, W143, A145, S146, T147, E148, Y151, G159, I161, K163, G171, S179,
- 25 Y181, S197, L199, Y214, E215 or R216, wherein said functional red fluorescent protein has a different fluorescent property compared to said Anthozoan red fluorescent protein (SEQ. ID. NO. 7), and wherein said functional red fluorescent protein is operably coupled to a first protein of interest,
- 30 ii) a functional green fluorescent protein, wherein said functional green fluorescent protein is operably coupled to a second protein of interest, and wherein said functional green

fluorescent protein and said functional red fluorescent protein undergo fluorescence energy transfer (FRET) when said first operably coupled protein of interest and said second operably protein of interest associate,

- 5 b) detecting FRET between said functional green fluorescent protein and said functional red fluorescent protein in the presence of said test chemical, and
- c) comparing the FRET in step b) to the FRET in a control cell in the absence of said test chemical.

10

80. The method of claim 79, further comprising the step of contacting said cell with an activator prior to the addition of said test chemical.

15

81. The method of claim 79, further comprising the step of detecting the viability of said cell

82. A test chemical identified by the method of claims 79.

20

83. A pharmaceutical composition comprising a test chemical identified by the method of claim 79.

84. The pharmaceutical composition of claim 79, further comprising a pharmaceutically acceptable carrier.

1/4




FIG. 1

2/4




FIG. 1 continued

3/4





FIG. 2

4/4

Wild Type



Cells Transformed with the retroviral
expression plasmid containing synthetic RFP




FIG. 3